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ABSTRACT 
Lyme borreliosis, more commonly referred to as Lyme disease, is the 
fastest growing zoonotic disease in North America with approximately 30,000 
confirmed cases and 300,000 estimated infections per year. In nature, the 
causative agent of Lyme disease, the bacterium Borrelia burgdorferi, cycles 
between Ixodes sp. ticks and small mammals. Humans become infected with 
Lyme disease after being bitten by an infected tick. The primary indicator of a 
Borrelia burgdorferi infection is a bull’s eye rash typically followed by flu-like 
symptoms with treatment consisting of a 2-4 week course of antibiotics. If not 
treated, later stages of the disease can result in arthritis, cardiovascular and 
neurological symptoms. Diagnosis of Lyme disease is challenging and 
currently requires a complex laboratory diagnostic using indirect detection of 
host-generated antibodies by a two-tiered approach consisting of an enzyme 
linked immunosorbent assay (ELISA) followed by IgM and IgG immunoblots. 
Although two-tier testing has provided an adequate approach for Lyme 
disease diagnosis, it has weaknesses including subjective analysis, complex 
protocols and lack of reagent standardization. Immuno-PCR (iPCR) is a 
method that combines ELISA-based detection specificity with the sensitivity of 
PCR signal amplification and has demonstrated increased sensitivity for many 
applications such as detection of disease biomarkers but has yet to be applied 
for diagnosis of Lyme disease. 
Herein, using iPCR and recombinant B. burgdorferi antigens, an assay 
for both the direct and the indirect detection of Lyme disease was developed 
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and demonstrated improved sensitivity for detection of B. burgdorferi 
antibodies using a murine model.  Moreover, we present evidence using 
human Lyme disease patient serum samples that iPCR using both multiple 
antigens and a unique single hybrid antigen is capable of achieving increased 
sensitivity and specificity compared to existing methodology. These data 
represent the first demonstration of iPCR for Lyme disease diagnosis and 
support the replacement of two-tier testing with a more simplified and 
objective approach. 
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CHAPTER ONE: 
INTRODUCTION 
Lyme Disease Background 
 
History 
Beginning in the early 1970s, a cluster of apparent rheumatoid arthritis 
cases occurring primarily among children and some adults in the areas 
surrounding Lyme, Connecticut captured the attention of the public health 
community.  A surveillance of the town resulted in 39 children diagnosed with 
reoccurring symptoms of large joint swelling and pain with some episodes 
lasting for extended periods of time [1].  An additional twelve adults either 
related or living in close proximity to the arthritic children were also diagnosed 
with signs and symptoms similar to those seen in the juvenile cases.  The 
investigation excluded juvenile rheumatoid arthritis as the cause of the 
epidemic on the basis that the prevalence of symptoms (particularly arthritis) 
was 100 times greater than that expected for juvenile rheumatoid arthritis for 
the surrounding Connecticut communities.  The disease was initially named 
Lyme arthritis to indicate the town and initial symptom observed.  Following an 
expansion of the clinical symptoms to involve both neurological and cardiac 
symptoms, the name was finally changed to Lyme disease [2]. 
The growing investigation revealed that about 25% of the patients had 
developed an erythematous cutaneous lesion that appeared to expand into a 
reddish rash composed of concentric rings similar in appearance to a ‘bull’s 
eye’.  The lesion typically appeared weeks before the onset of disease 
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symptoms and resembled a similar lesion that had been described much 
earlier in Europe that was associated with being bitten by an Ixodes rincinus 
tick [3].  Investigators followed patients with cutaneous lesions [4] and 
subsequently observed a range of symptoms including arthritis, neurological 
and cardiac abnormalities [5].  The addition of neurological and cardiac 
involvement underscored the complex manifestation of the disease that 
appeared to involve multiple organ systems [2, 5]. 
The evidence presented for the European rash and its association with 
a tick bite led to a similar hypothesis in the Connecticut cases that a local 
Ixodes species was associated with the disease [6].  This conclusion was also 
further supported by the fact that many of the children diagnosed with arthritis 
either lived or routinely played adjacent to wooded areas where Ixodes ticks 
were commonly found.  It was also noted that the children’s initial symptoms 
typically started during the summer months, which coincided with the peak of 
tick season.  Many of the children reported having a skin rash similar in 
description to an erythema migrans (EM), or ‘bull’s-eye’ rash prior to 
developing arthritis that was often associated with a tick bite [1].  Another 
important piece of supporting evidence was that patients exhibiting the EM 
rash that were treated with penicillin showed a shortened duration of the rash 
and lessened subsequent arthritis [7].  The affective treatment of the disease 
with antibiotics provided a key piece of evidence that a bacterial infection was 
most likely associated with disease progression [7]. 
Similar studies at the time surrounding a suspected epidemic of 
babesiosis caused by a parasite in Shelter Island, New York provided the next 
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critical step in unravelling the cause of the disease.  Dark field microscopy of 
organisms isolated from Ixodes scapularis adult ticks collected as part of a 
serosurvey for the Shelter Island cases identified coil shaped bacteria known 
as spirochetes in the samples.  These bacteria were further cultured and 
confirmed in a spirochete specific medium thus confirming the presence of the 
organism.  Serum from individuals exhibiting symptoms of Lyme disease from 
the Connecticut group were then tested using the tick isolated organisms and 
showed strong sero-reactivity to the newly cultured spirochetes [8].  This 
indicated the Lyme disease patients had most likely been infected with the 
same organism.  The final piece of evidence was uncovered when the same 
tick isolated spirochetes that exhibited sero-conversion in Lyme patients were 
also isolated from skin samples of patients with the EM rash [9].  Further 
investigations also isolated the same organism from white-footed mice in the 
local Connecticut communities [10] thus identifying the main reservoir of the 
bacterium [11].  With the reservoir identified and reisolation of the causative 
bacteria from human patients exhibiting the characteristic EM, a strong 
explanation for the arthritis epidemic observed in areas surrounding Lyme, 
Connecticut had been determined.  The future of Lyme disease research 
would now focus on the biology of the bacteria, transmission, human infection 
and diagnosis of the disease. 
Lyme Disease Infection 
Historically, there have been approximately 30,000 confirmed cases of 
Lyme disease per year seen across almost every state with the majority of 
  4 
cases concentrated in the Northeastern and Midwestern states [12].  
Representative statistics for the CDC confirmed cases of Lyme disease in 
2011 are depicted by state in Figure 1.  More recently, the CDC has revised 
these statistics to suggest an approximate estimate of 300,000 infected cases 
per year [13]. 
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Figure 1. United States 2011 CDC confirmed Lyme disease cases. Cases are determined based on the state of residence and 
not the state where the infection was contracted. Case number ranges are depicted based on the color scale with the exact 
number of cases listed by State in the bottom table [14, 15].  
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The primary indicator of Lyme disease infection by the B. burgdorferi 
spirochete is the appearance of an EM or ‘bull’s eye’ rash that is typically 
observed in approximately 75% of cases [16].  An oval or circular rash can be 
observed over days or weeks following a tick bite that begins as a small red 
spot at the site of the bite [6].  More specific to Lyme disease, the rash 
continues to form a red ring surrounding a clear area with a red spot in the 
center very similar in appearance to the concentric circles of an archery 
target. The rash, which typically occurs at the site of the tick bite, can take a 
few weeks to fully present in infected patients and can vary in size from a 
silver dollar to covering the entire surface of the torso [17].  Following the 
spread of infection, additional similar rashes both with and without a bull’s eye 
center can manifest at additional locations distal to the original tick bite and 
indicate dissemination of the Lyme disease spirochete [18].  Although the 
bull’s eye rash is the hallmark symptom of Lyme disease, other symptoms 
similar to common viral infections such as fever, aches, stiffness and fatigue 
can accompany infection and can last for longer periods of time than other 
common infections [19].  Assuming the infection goes untreated and following 
organism dissemination, additional symptoms can be observed including 
arthritis, nervous system complications and more rarely can involve cardiac 
symptoms as well [20].  In even rarer cases, B. burgdorferi infection has been 
documented to cause severe fatigue [21], eye inflammation [22] and hepatic 
liver disease [23]. 
Recommended treatment for Lyme disease is a 2-4 week course of 
antibiotics [24].  Although typically successful at resolving the infection, 
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approximately 15% of patients will continue to experience symptoms of 
muscle and joint aches or fatigue following treatment [25].  Pain symptoms 
can sometimes persist for 6 months or more following treatment after which 
the disease is often referred to as ‘Chronic Lyme Disease’ due to the inability 
to resolve symptoms with standard antibiotic treatment [25].  If symptoms 
persist following treatment the condition is more appropriately being referred 
to as ‘Post-treatment Lyme Disease Syndrome’ (PTLDS) [26].  Although the 
cause of PTLDS remains elusive, it has been suggested that unresolved 
symptoms result from residual tissue damage due to overstimulation and/or 
self-recognition of the immune system resulting from the original spirochete 
infection [27].  Lyme disease is suspected to be similar to other human 
infections including Chlamydia [28] and Campylobacter [29] in which similar 
‘auto-immune’ reaction based diseases have been observed following 
successful treatment of the infection.  In direct contrast to the residual tissue 
damage theory, additional theories have been postulated that unresolved 
symptoms are a reflection of persistent infection with Borrelia burgdorferi that 
was not cleared with an initial course of antibiotics [30].  Select groups of 
health care providers have advised their patients that based on this theory 
their conditions warrant a longer term regimen of antibiotic treatment beyond 
the recommended 2-4 week course of treatment [31].  This is in direct 
contradiction to studies that have demonstrated that Lyme disease patients 
who received prolonged courses of antibiotics did not result in an outcome 
significantly better than patients treated with a placebo [32, 33].  Regardless 
of the cause of PTLDS, it continues to be a controversial issue [34] that 
  8 
underscores the importance and strong need for improved Lyme disease 
diagnosis. 
Ixodes scapularis Life Cycle 
The only known insect vectors of Lyme disease in the United States 
are Ixodes scapularis, commonly known as the deer or black-legged tick in 
the Eastern part of the United States and the closely related Ixodes pacificus 
or western black-legged tick in the Western part of the United States [35]. 
Approximate distributions for each species are shown in Figure 2.  I. 
scapularis and I. pacificus are both hard-bodied ticks that display a two-year 
life cycle that is dependent on a fresh blood meal from a vertebrate to 
advance to the next stage in each cycle [36]. 
 
Figure 2. Black-legged tick distribution. States where each species can be 
found are shown [15, 37]. 
  9 
The deer tick proceeds through three distinct stages of growth over its 
life cycle that includes the larval, nymph and adult stages (Figure 3). It takes 
approximately two years for the tick to proceed from an egg through all three 
developmental stages, reproduce, subsequently lay eggs and ultimately 
expire at the end of the cycle [38]. The tick life cycle begins with egg hatching 
and emergence of larvae in spring. This is then followed by development into 
nymphs the ensuing year after the first blood meal and finally by development 
into adults the subsequent year after the second blood meal [39]. B. 
burgdorferi infection is acquired from infected nymphs or adults with 
uninfected larvae posing no danger to humans due to the absence of the 
infecting organism [40]. People are usually able to notice attached and 
feeding adult ticks making them easy to remove prior to spirochete infection. 
A large number of Lyme disease cases originate from feeding nymphs that 
are smaller and more difficult to notice. Hence, the majority of Lyme disease 
cases are reported during the summer months with very few cases reported in 
the spring and fall [39]. 
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Figure 3. Black legged tick life cycle.  The two-year life cycle of the Ixodes tick 
begins with eggs laid by the female in spring that proceed to hatch into larvae 
that partake of their first blood meal in the summer.  This is followed by 
molting into the nymph form that then overwinters and remerges the following 
spring and again partakes of a blood meal followed by molting into the adult 
form that feeds a third time in late fall or early spring of the second year and 
followed by egg laying in late spring and a repetition of the cycle. 
The larval form comprises the first stage of the tick infectious cycle 
[41].  The adult female Ixodes tick lays its eggs in the spring, which then hatch 
into larvae during late summer. The larvae, which are no bigger than a pin 
head, begin to peak in activity in late August [42].  A small mammal or bird 
that contacts the awaiting larvae on the ground then becomes the first host for 
the tick in the first stage of its life cycle. The larva uses its mouth-parts to 
attach to the host and then begins its first blood meal.  Over a period of 3-5 
days the tick swells with the blood meal from the host [38]. It is at this stage 
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that the spirochete can make its first transfer between hosts.  If the mammal 
or bird had been previously infected with the organism from a subsequent tick 
bite, the larva would now become infected with the Lyme disease spirochete.  
The spirochete utilizes large numbers of wild infected hosts (such as white-
footed mice) as a reservoir that can continue to infect new larvae through 
each transmission cycle [43].  Although mice and other small mammals are 
the principal reservoir for B. burgdorferi, ground-feeding birds can serve as 
natural reservoirs as well [44].  Since larval ticks require a blood meal to 
become infected, freshly hatched larvae cannot transmit Lyme disease to 
animals or humans and hence pose no danger for passage of the disease.  
Instead, larvae act as the first stage of the infectious life cycle through feeding 
on ‘reservoir’ hosts. Once a larvae has fed, it will not feed again until the next 
stage in its life cycle [45]. 
The second stage of the tick life cycle poses the largest threat of 
human infection and is characterized by the nymphal form of the tick [45].  
After completing their blood meal at the end of the first stage in their life cycle, 
the larvae disassociate from their host and return to the ground where they 
molt and metamorphose into nymphs.  This occurs at the end of the fall after 
which the nymphs become dormant through the winter and early months of 
spring.  Typically around May, the nymphs awaken from their inactive 
overwinter state, climb onto nearby vegetation and await the opportunity to 
interact with a new small mammal or bird host as they pass by [46].  The 
nymph takes the opportunity to attach to the host animal on which it will feed 
for approximately five days.  During feeding, the nymph will engorge with 
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blood and swell many times its original size.  If the nymph had been infected 
during its blood meal in the larval stage, it can transmit infectious B. 
burgdorferi to its new host after about 48 hours of feeding [47].  Similar to the 
larval stage, if the nymph is uninfected at this point in its life cycle, it can 
become infected if its host already carries the Lyme disease pathogen from a 
previous infectious tick bite. Surveys of ticks in the highly endemic Northeast 
and upper Midwest have found that about 25% of nymphs contain and can 
transmit B. burgdorferi [48].   Regrettably, because of frequent outdoor activity 
during the spring months, humans will often come into contact with 
populations of infected nymphs during their peak activity, which can occur 
from late May to the end of July.   Nymphs normally feed on small mammal 
and bird hosts but will feed upon humans, pets and other domestic animals if 
the opportunity presents itself.  Although not as small as larvae, nymphs 
reach the size of about a poppy seed [39] which makes them difficult to notice 
when they are attached to visible areas on the skin and even more difficult to 
locate in less conspicuous areas of the body such as the scalp or armpits.  
Hence, nymphs are responsible for transmission of a large proportion of 
human Lyme disease cases [45]. 
 The third and last stage of the tick life cycle involves progression to the 
adult form followed by reproduction.  After finishing its blood meal, the nymph 
releases from its host, falls to the ground and begins the process of molting or 
transforming into the adult and reproductive stage of its life cycle [49].  After 
completing development in early fall, the adult tick climbs and perches on 
vegetation a few feet off the ground and awaits another host such as a deer or 
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other large mammal to complete its last blood meal.  Late October and early 
November mark the peak of activity for adult tick feeding [50].   Due to the 
increased potential for infection at either the larval or nymph stage, a higher 
percentage of adult ticks surveyed in endemic areas have been found to be 
infected with B. burgdorferi with as much as 50% of the population in the 
Northeast testing positive for the Lyme disease spirochete [51].  In contrast to 
infection by bites from nymphs, fewer cases of Lyme disease are associated 
with adult tick bites because of their larger size.  When fully engorged with a 
blood meal, adults can reach the size of a small grape and hence are much 
more likely to be detected and removed prior to the 36 hours required for 
disease transmission [52]. 
At the end of the fall and beginning of the winter months, both fed and 
unfed adult ticks migrate underneath ground cover and surface vegetation to 
overwinter.  Adult ticks become inactive in temperatures below 45° F which 
means winter temperatures in the endemic Northeast and upper Midwest 
states keep ticks inactive in a dormant state until temperatures rise again in 
late February to the beginning of March [53].  As the temperature warms, 
adult ticks will again resume their attempts to acquire a host blood meal prior 
to actively seeking a mate for reproduction which peaks in typically March to 
the beginning of April [41].  Tick mating in the spring can occur either while 
attached to a host or following a blood meal and is followed by the laying of 
eggs by the female underneath leaf litter and other ground cover.  An adult 
female tick can lay up to 3,000 eggs in a litter after which she will die and the 
eggs will hatch later that summer completing the two-year life cycle [54]. 
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Borrelia burgdorferi Biology 
Borrelia burgdorferi, the causative agent of Lyme disease in the United 
States is a spirochete bacterium that appears gram negative by safranin 
staining, but is not typically classified as either gram positive or negative [55].  
The other two Lyme disease causing species of the genus Borrelia are B. 
garinii and B. afzelii, which are responsible for the majority of cases in Europe 
[56].  Of the three species, B. burgdorferi is unique in that it has an extensive 
distribution encompassing most of the northern hemisphere including both 
North American and Europe [57].  B. burgdorferi is transmitted by ticks, 
requires small mammals as hosts to complete its life cycle and causes 
disease in humans and other mammals by causing an inflammatory response.  
The bacteria are able to adapt to the mammalian environment by dramatically 
up-regulating or down-regulating gene expression as it is transmitted from the 
infected tick to the mammalian host [45]. 
B. burgdorferi causes a primary infection by moving into the 
bloodstream of the infected mammal and colonizing different tissue sites.  
Through chemotaxis and unique mechanisms of motility, the organism 
continues to disseminate throughout the body leading to a more advanced 
stage of infection [58].  A number of B. burgdorferi proteins have been 
implicated in host cell adherence through interactions with surface proteins 
and extracellular matrix components.   As a result of these proteins, the 
organism is capable of blood vessel penetration, adherence to endothelial 
cells and interacting with a number of different tissues [59].   For example, B. 
burgdorferi stimulates plasmin on the bacterial surface and has the capability 
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to induce host protease production which aides in its dissemination and 
ultimately leading to tissue damage and inflammation [60].  B. burgdorferi 
infection can lead to arthritic, dermatological, cardiovascular and neurological 
symptoms across the multiple stages of infection in spite of low numbers of 
microorganisms in tissues [61].  Unique mechanisms to evade the immune 
system allow the spirochete to persist for long periods of time post infection in 
the presence of strong antibody and cellular host responses [62].  
Interestingly, the pathogen has not been shown to produce any toxins to aide 
its persistence and disease manifestation over either short or extended time 
periods [45]. 
Much of the adaptive nature of the organism is attributed to its unique 
genome [63].  Sequencing of the B. burgdorferi genome confirmed the 
presence of an approximately 900 kilobase pairs (kbp) linear chromosome 
and an extra-chromosomal complement of linear and circular plasmids in the 
range of 55-220 kbp [64].  The genome sequence for multiple strains of all 
three Lyme disease causing Borrelia species (B. burgdorferi, B. afzelii, B. 
garinii) [65, 66] as well as multiple related species (B. hermsii, the causative 
agent of relapsing fever) [67] have been completed or are currently underway.  
A large number of housekeeping genes, which are conserved in sequence 
and organization across the genus, are carried on the chromosome.  The up 
to 22 circular and linear plasmids, which can vary in number by 
species/isolate and are much more variable in sequence than the 
chromosome, encode a large number of differentially expressed surface 
proteins known to interact with the B. burgdorferi tick vector and mammalian 
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host [68].  One of the more studied strains is the B. burgdorferi B31 type 
strain, which possesses nine circular and twelve linear plasmids and a small 
linear chromosome.  Beyond coding gene sequences, B. burgdorferi plasmids 
are unusual in that they contain a large number of paralogous and 
pseudogene sequences as well as genes essential for host infection [63].  In 
addition, many genes have been experimentally deleted from B. burgdorferi 
plasmids with no resulting detectable phenotype [69]. 
B. burgdorferi has been shown to modulate its expression profile in 
response to the numerous environmental cues encountered throughout its 
infectious cycle and can therefore demonstrate variation in antigen 
presentation throughout infection [70-86].  For example, during early stages of 
infection B. burgdorferi is capable of attachment to host tissues through 
expression of different adhesins that can bind integrins [87], fibronectin [88, 
89], proteoglycans [90], glycosaminoglycans [91] and laminin [92].  B. 
burgdorferi has also been shown to express proteins known as complement 
regulator-acquiring surface proteins (CRASPs) that bind factor H and prevent 
the spirochete from being killed by the complement arm of the innate immune 
system [93].  Crucial to clearance of the pathogen in the mammalian host is 
development of a humoral or antibody response against specific B. 
burgdorferi antigens [94].  Several well-known immunodominant antigens are 
expressed by B. burgdorferi early in disease including flagellin [95], OspC [96] 
and BmpA [97].  As the disease progresses further resulting in spirochete 
dissemination, additional antigens are known to illicit an immune response as 
determined by immunoblot [98, 99].  B. burgdorferi has been shown to also 
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utilize the VlsE lipoprotein which undergoes antigenic switching through a 
recombination mechanism to further avoid the immune system [100] and 
consequently this protein has proved useful as an immunodiagnostic target 
[101].  More recent studies have focused on screening large numbers of B. 
burgdorferi proteins using protein arrays with the aim of discovering antigens 
that illicit a strong immune response [102] toward the ultimate goal of 
contributing to development of the next generation of Lyme disease 
diagnostics. 
Current State of Lyme Diagnostics 
Due to the fact that Lyme disease can present with symptoms like 
fever, pain and fatigue which are very similar to other common illnesses, 
treating physicians may have difficulty diagnosing a B. burgdorferi infection 
based on these symptoms alone [103].  Although the ‘bull’s eye’ rash or EM is 
the only unique Lyme disease symptom it is only typically detected in about 
75% of patients infected with B. burgdorferi and can be difficult to detect 
based on size and/or location on the head or torso [17].  To further complicate 
the diagnosis, people may not recall or detect the actual tick bite required for 
transmission of the pathogen.  This is typically due to the fact that many 
people are bit by the Ixodes tick in the nymph stage, which is small and 
difficult to detect [104].  Assuming symptoms match that of Lyme disease and 
in the absence of an EM rash, physicians will then rely on a detailed medical 
history to rule out additional potential infectious agents and/or diseases.  The 
physician will look for specific details relating to B. burgdorferi exposure 
  18 
including if the person frequents areas endemic for Lyme disease, if a tick bite 
was detected or suspected and what part of the year symptoms first appeared 
(i.e., summer months).  This information is then combined with a thorough 
physical examination for evidence of tick bites and laboratory diagnostic tests 
that are used to further aide in diagnosis [105]. 
Two-Tier Laboratory Diagnostic 
The accepted method of Lyme disease laboratory diagnosis is indirect 
detection of host generated antibodies to Borrelia burgdorferi, the causative 
agent of the disease [106].  It takes days to weeks for an individual infected 
with B. burgdorferi to generate sufficient IgM or IgG antibody titers, 
respectively, against the bacteria to be detected using laboratory based 
diagnostics [107].  The current accepted method of serologic testing for Lyme 
disease utilizes a 2-tier approach that was established in 1995 [106]. The 
method entails testing of a serum sample using a first-tier enzyme linked 
immunosorbent (ELISA) assay employing B. Burgdorferi whole cell sonicate 
or recombinant antigens that results in high sensitivity but somewhat reduced 
specificity.  A negative first-tier result means no further testing of the 
specimen is recommended.  A positive first-tier result is followed by retesting 
of the serum sample by distinct IgM and IgG immunoblots (or western blots) 
that typically employ B. burgdorferi whole cell sonicate.  An individual is 
considered to be diagnostically positive for Lyme disease only if the ELISA 
(first-tier) and the immunoblot (second-tier) are both positive. 
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Each step of two-tier testing requires different analytical criteria and 
subsequent results are either quantitative (ELISA) or qualitative (immunoblot) 
based on the tier.  The first-tier ELISA measures a quantitative immune 
response to typically a single B. burgdorferi antigen or immunogenic peptide 
or a limited number of recombinant B. burgdorferi antigens.  Increased values 
are typically correlated with the numbers of B. burgdorferi antibodies in the 
serum and provide a measure of immune response level.  First-tier results are 
categorized as positive, equivocal or negative based on pre-established value 
ranges [108].  Second-tier testing using IgM and IgG immunoblots provides a 
qualitative measurement of antibody response and typically employs the use 
of B. burgdorferi whole cell sonicate [99].  There are a small number of kits 
approved for use as a second-tier Lyme disease diagnostic that employ 
multiple recombinant B. burgdorferi antigens [109].  Second-tier IgM 
immunoblot results are considered positive if two of three B. burgdorferi 
specific bands (23, 39 and/or 41 kDa) are detected above a particular signal 
threshold [106].  Second-tier IgG immunoblot results are considered positive if 
five of ten B. burgdorferi specific bands (18, 21, 28, 30, 39, 41, 45, 58, 66 
and/or 93 kDa) are detected [106].  Immunoblot second-tier testing employed 
during the first 4 weeks of disease includes testing of both IgM and IgG 
antibody reactivity.  Due to the likelihood of a false-positive test result for IgM 
indicating a false active infection in later stage patient samples, IgM 
immunoblot results are not considered reliable for patients with suspected 
illness greater than 4 weeks in duration [110]. 
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Two-tier testing has provided an adequate approach for Lyme disease 
diagnosis but suffers from certain weaknesses including the subjectivity and 
complexity of immunoblot analysis as well as non-standardized lysate 
preparations and antigen sources [111].  For these reasons, immunoblot 
analysis and two-tier results have been shown to vary from laboratory to 
laboratory based on the test strategy used for detection of host antibodies 
resulting from the particular kit used [112]. Differences between test results 
largely reflect the antigen variability across different manufacturers [111].  As 
detailed above, B. burgdorferi antigen expression can vary significantly based 
on the strain and the conditions used to cultivate the organism.  More 
recently, in an effort to standardize the antigens used between Lyme disease 
diagnostics it has been suggested that the use of whole cell sonicate as a 
source of antigens be replaced with the utilization of a combination of 
recombinant B. burgdorferi antigens [109].  Although a single antigen would 
further simplify a diagnostic test for Lyme disease, no single antigen tested to 
date has shown success at diagnosing Lyme disease across all stages of the 
disease [111]. A more recent ELISA that targets the conserved VlsE C6 
peptide of B. burgdorferi has been developed and proposed as a single-tier 
test.  Although it appears to provide increased sensitivity for early stage 
disease diagnosis, the antigen shows no increased sensitivity for later-stage 
disease diagnosis with overall lower specificity observed when compared with 
two-tier testing [113].  Hence, despite its drawbacks, two-tier testing remains 
the recommended and current method for laboratory diagnosis of Lyme 
disease [114]. 
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Additional Methods For Diagnosis Of Lyme Disease In Development 
Although two-tier testing remains the mainstay of clinical Lyme disease 
diagnostics, it is important to emphasize that additional methods have been 
developed and tested.  These methods include both direct detection of the 
presence of spirochetes and indirect detection by serological methods.  Direct 
methods include microscopic observation of whole spirochetes from patient 
samples, detection of B. burgdorferi-specific antigens, in vitro culture of 
spirochetes from patient samples and polymerase chain reaction amplification 
(PCR) of spirochete nucleic acid targets [111].  Dark field microscopy is useful 
for specimens where large numbers of spirochetes are expected but the value 
of diagnosis by microscopy in the clinical laboratory is limited due to the low 
organism density in clinical samples and similarity to host tissue structures 
[55].  Direct detection of B. burgdorferi antigens by ELISA and dot blot is 
rarely used in a clinical setting due to low sensitivity [115] and poor specificity 
and reproducibility [116].  Culture of B. burgdorferi from patient samples is 
also not routinely used in a clinical setting due to variations in in vitro growth 
medium, long sample incubation periods (minimum of 12 weeks), and most 
importantly very low sensitivity due to small numbers of spirochetes present in 
blood during infection [111].  Although it appears to be a promising approach 
for direct detection of spirochetes, PCR has not been widely accepted as a 
laboratory diagnostic for Lyme disease due to low sensitivity in blood and 
cerebral spinal fluid and accidental laboratory contamination of samples with 
small quantities of target DNA that can lead to potential false-positive results 
[117].  For these reasons, indirect detection of infection by serology using 
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ELISA and western blot has remained the method of choice in clinical 
settings.  With inherent limitations to two-tier testing discussed above, there 
exists the opportunity for improvements to current Lyme disease diagnostics. 
Immuno-PCR 
 
Technique Summary 
Immuno-PCR (iPCR) as first described by Sano et al. in 1992 [118] 
combines the capability for signal amplification afforded by PCR with the 
flexibility of an ELISA based approach, which can result in overall 
improvement of conventional antigen detection methodology.  The basic 
design of the assay depends on the analyte (antigen or antibody) being 
measured.  Early versions of the technique used gel electrophoresis to 
measure the amount of PCR product generated.  This not only limited the 
range of quantification that could be used for immuno-PCR but was also 
laborious, had low sensitivity and provided limited applicability for quantitative 
measurement.  With the incorporation of real-time PCR into the existing 
protocol, the amount of reporter oligonucleotide could be quantified with high 
sensitivity and accuracy over a wide concentration range providing concise 
and consistent measurements of antigens within a sample [119]. It was also 
through elimination of the post-PCR processing steps used for gel 
electrophoresis that both the total assay time as well as overall risk of 
laboratory contamination were significantly reduced [119]. 
Following development and optimization by researchers of the iPCR 
protocol for sensitive and quantitative detection of proteins in samples, studies 
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were undertaken to determine the sensitivity of the approach as compared to 
standard ELISA protocols.  Results indicated that typically 100-10,000-fold 
detection limit improvements were observed in almost all applications [120].  
iPCR has been applied for sensitive detection of a variety of targets including 
viral antigens [121], bacterial antigens [122], prions [123] and bacterial toxins 
[124].  There has been only a limited number of iPCR studies focused on host 
generated antibody detection, with successful application to the measurement 
of mumps-specific IgG in human patient serum [125].  
Application of iPCR for Lyme Disease 
Although two-tier testing based on ELISA followed by immunoblot is 
the current accepted method of Lyme disease diagnosis, a better approach 
would be to increase the sensitivity of the current system through 
incorporation of PCR signal detection combined with the use of recombinant 
antigens.  The issues posed by the current approach including limited 
sensitivity, subjectivity of analysis and inconsistency in capture antigens have 
the potential to be alleviated through the application of iPCR and recombinant 
B. burgdorferi in vivo-expressed antigens.  An iPCR-based assay design for 
indirect detection first requires antigens specific for host generated antibodies 
to be immobilized to a surface, which can include a microtiter plate, magnetic 
beads or any suitable vessel.  The patient sample is then exposed to the 
antigen-coated surface and any antibodies present in the sample will bind the 
antigens immobilized on the surface.  A secondary reporter antibody coupled 
to a DNA oligonucleotide is then added and binds to any human antibodies 
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that were captured by the surface bound antigens.  The DNA reporter 
oligonucleotide attached to the secondary antibody is then amplified by PCR 
following extensive washing of the complex to remove any unbound reagents.  
By determining the cycle number where the exponential phase of amplification 
is achieved during PCR, the amount of antibody present in the patient sample 
can be quantitatively determined.  iPCR has already demonstrated increased 
sensitivity for other applications and use of recombinant antigens could 
provide both standardized reagents as well as provide a potential to combine 
antigens from multiple species and strains in unique configurations [126].  
Beyond just sensitivity, the multiplex capabilities, objective analysis and ease-
of-use of iPCR [127] make it a strong candidate for development of a new 
Lyme disease diagnostic.  The workflow for iPCR could also be further 
simplified and automated by transfer to automated systems and even 
microfluidic point-of-care diagnostic platforms as has been accomplished for 
similar protocols [128].  Reduction in the assay complexity would provide the 
capability for more routine, affordable and high-throughput diagnostic testing 
of Lyme disease patients. 
The overall goals of the research detailed in this dissertation were to 1) 
develop an iPCR protocol suitable for detection of a B. burgdorferi infection, 2) 
apply the protocol using in vitro expressed recombinant antigens for direct 
detection of spirochetes and indirect detection of host generated antibodies in 
an infected murine model and 3) determine the level of sensitivity and 
specificity of the optimized protocol with more comprehensive testing of 
human Lyme disease patient and healthy donor samples.  
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CHAPTER TWO: 
ENHANCED DETECTION OF HOST RESPONSE ANTIBODIES TO 
BORRELIA BURGDORFERI USING IMMUNO-PCR 
Preface 
The first complete draft of the chapter was written by MDH. Comments 
from MWJ and reviewers were incorporated into the final version presented 
here. This chapter was published previously and is reprinted here with 
permission.  Copyright © American Society for Microbiology, Halpern MD, 
Jain S, Jewett MW. 2013. Enhanced detection of host response antibodies to 
Borrelia burgdorferi using immuno-PCR. Clin Vaccine Immunol. 20(3):350. 
DOI: 10.1128/CVI.00630-12. 
Introduction 
Lyme disease is the leading vector-borne bacterial disease in the world 
with approximately 30,000 cases reported in the United States alone each 
year [37]. Lyme disease has been characterized as the fastest growing 
zoonotic disease in North America. According to the Centers for Disease 
Control and Prevention (CDC), the number of clinical cases of Lyme disease 
has more than doubled over the past 10 years making this emerging 
infectious disease a major public health concern [37]. Accurate diagnosis is 
currently the greatest challenge for the clinical management of Lyme disease. 
Misdiagnosis is common as the clinical manifestations of the disease are not 
unique and detection of a B. burgdorferi infection is difficult and prone to 
misinterpretation [111, 129]. Different approaches for laboratory testing, such 
as microscopy, genomic DNA amplification and serology have been examined 
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with currently accepted laboratory diagnostics relying primarily on detection of 
a serological response to B. burgdorferi antigens [111, 130, 131]. 
 Current methods for detection of Lyme disease in a clinical setting as 
approved by the CDC entail a two-tiered approach using a first tier enzyme 
immunoassay (EIA) followed by a second tier immunoblot for both IgM and 
IgG B. burgdorferi specific antibodies using whole cell B. burgdorferi lysates, 
recombinant antigens or various combinations depending on the commercial 
kit used [111]. Although adequate, the approach suffers from certain 
drawbacks including the subjectivity of immunoblot analysis and the lack of 
standardization of antigen source and lysate preparations. These challenges 
have resulted in discordant results between test strategies for detection of 
host antibodies based on the kit used [112] largely due to lysate/antigen 
reagent variability [111]. The most effective approach appears to be the use of 
a combination of recombinant antigens to replace whole organism sonicates 
as no single antigen has been found to be sufficient for accurate diagnosis 
[111]. 
Other methods for detection of Lyme disease include live culture and 
approaches employing polymerase chain reaction (PCR). Live culture has 
shown limited success in a clinical setting, is time consuming and requires 
complex media that have a limited commercial supply [111]. PCR appears to 
be the most promising method for direct detection of spirochetes but has not 
been widely accepted for laboratory diagnosis due to low sensitivity in 
cerebral spinal fluid and blood and the potential false-positive results due to 
accidental laboratory contamination of samples with small quantities of target 
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DNA [117]. An improved approach would be to utilize the sensitivity of PCR 
combined with an antigen based detection system that is much less 
susceptible to false positive results. 
Immuno-PCR (iPCR) was first introduced by Sano et al. in 1992 [118] 
and combines the amplification power of PCR with the versatility of EIA 
resulting in improved conventional antigen detection sensitivity. Using iPCR, a 
typical 100-10,000-fold improvement over the detection limit of the EIA has 
been obtained in almost all applications [120]. iPCR has been used to detect 
viral antigens [121], bacterial antigens [122], prions [123] and bacterial toxins 
[124]. There has also been a limited application of iPCR for antibody 
detection, such as the measurement of mumps-specific immunoglobulin G in 
human serum [125]. 
The combination of an iPCR approach and recombinant B. burgdorferi 
in vivo-expressed antigens has the potential to alleviate a number of the 
issues posed by Lyme disease diagnostics. Recombinant antigens not only 
have the potential to standardize the reagents used for Lyme disease 
diagnostics but also provide the opportunity to combine antigens from multiple 
strains/species. The sensitivity, ease-of-use, objective analysis and multiplex 
capabilities of iPCR [127] also makes it an ideal platform for Lyme disease 
detection. Furthermore, iPCR has the ability to be translated to an automated 
point-of-care diagnostic platform using microfluidics [128] that may allow 
routine, high-throughput and affordable diagnostic testing of Lyme disease 
patients. The goal of this research was to explore the initial application of 
iPCR using recombinant antigens for detection of either host generated 
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antibodies or direct detection of spirochetes in B. burgdorferi infected 
samples. 
 
Materials and Methods 
 
Bacterial Strains  
B. burgdorferi clone B31 A3 [132] and B31 A34/pBSV2G-loxP-flaBp-
gfp [133] were used in these studies. Spirochetes were grown in liquid 
Barbour-Stoenner-Kelly (BSK) II medium supplemented with gelatin and 6% 
rabbit serum [134] and plated in solid BSK medium as previously described 
[135]. All spirochete cultures were grown at 35C and supplemented with 
2.5% CO2. Gentamicin was used at 40 g/ml. Escherichia coli strains DH5α 
and BL21 (Novagen, Billerica, MA) were grown in LB broth, on LB agar plates 
or in Magic Media (Invitrogen, Carlsbad, CA) containing 100 g/ml ampicillin.  
Mouse Infections 
The University of Central Florida (UCF) is accredited by the 
International Association of Assessment and Accreditation of Laboratory 
Animal Care. Protocols for all animal experiments were prepared according to 
the guidelines of the National Institutes of Health and approved by UCF’s 
Institutional Animal Care and Use Committee. For the serological detection 
experiments, the hair on the upper backs of three mice (C3H/HeN, 6- to 8-
week old females; Harlan Laboratories, Inc, Dublin, VA) was removed by 
shaving and the mice were needle inoculated intradermally on the upper back 
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with B. burgdorferi strain B31 A3 at a dose of 1x105 spirochetes divided 
between two 50 l inoculations. The number of spirochetes inoculated into 
mice was determined using a Petroff-Hausser counting chamber and verified 
by colony forming units (cfu) counts in solid BSK medium. Total plasmid 
content of each inoculum was confirmed to be as expected [136]. Whole 
blood samples were collected from the three inoculated mice as well as one 
non-inoculated mouse by submandibular bleed pre-inoculation and at days 1, 
3, 4, 7, 9, 11, 14, 16, 18 and 21 post-infection. The coagulated blood was 
spun at 4,000xg for 9 minutes to prepare serum. For the spirochete detection 
experiments, six mice (C3H/HeN, 6-8 week old females, Harlan Laboratories, 
Inc, Dublin, VA) were inoculated intradermally with B. burgdorferi strain B31 
A3 at a dose of 1x105 spirochetes. Approximately 50 l of blood were 
collected by submandibular bleed from all mice prior to inoculation. 
Subsequently, to prevent complications due to oversampling, approximately 
50 l of blood/mouse were collected every day from groups of two mice so 
that each group of two mice was bled every three days over a time period of 
14 days. All blood samples (pre- and post-inoculation) were supplemented 
with an equal volume of 0.5M sodium EDTA to prevent coagulation.  
Similar to plating of in vitro grown B. burgdorferi, 50 l of blood from each 
mouse was combined with BSK plating medium [135] supplemented with a 
Borrelia antibiotic cocktail consisting of 20 l /ml phosphomycin (MP 
Biomedicals, Santa Ana, CA), 50 l /ml rifampicin (Fisher Scientific, Waltham, 
MA ) and 2.5 l /ml amphotericin B (Fisher Scientific, Waltham, MA ), all 
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solubilized in 20% DMSO, poured into sterile petri plates, allowed to solidify 
and incubated as indicated above for approximately 7 days until B. burgdorferi 
colonies were visible in the solid medium. 
Immunoblot and C6 ELISA 
Total B. burgdorferi lysate for immunoblot analysis was prepared from 
a 500 ml culture of 1x108/ml B. burgdorferi B31 A3. Spirochetes were 
harvested by centrifugation and washed two times in 30 ml phosphate 
buffered saline, pH 7.4 (PBS). Washed cells were resuspended in 30 ml PBS 
and disrupted by sonication on ice using a Misonix model S-4000 sonciator at 
40% amplitude for four repetitions at 20 seconds each. Total protein in the 
sonicate was normalized to 1 mg/ml with PBS based on absorbance at 280 
nm and 75 g of protein were separated by 12.5% polyacrylamide gel 
electrophoresis. Following protein transfer, nitrocellulose membranes were 
incubated for 1 hour with pre- and post- inoculation mouse sera diluted 1:200 
in Tris buffered saline/0.05% tween, pH 7.6 (TBST), washed twice with TBST, 
incubated with HRP-conjugated goat anti-mouse IgG/IgM (Chemicon 
International, Billerica, MA) for 1 hour, washed twice with TBST and the signal 
was detected using the SuperSignal West Pico Chemiluminescent Substrate 
Kit (Thermo Scientific, Rockford, IL). The C6 B. burgdorferi ELISA was 
performed according to manufacturer’s protocol (Immunetics, Boston, MA) 
with the exception of the use of HRP-conjugated goat anti-mouse IgG/IgM 
secondary (Chemicon International, Billerica, MA) at a 1:5000 dilution in place 
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of the anti-human reporter antibody provided with the kit when mouse sera 
were analyzed. 
Cloning and Expression of Recombinant GST Tagged Antigens 
In frame glutathione-S-transferase (GST) fusion proteins for OspC, 
BmpA and the VlsE C6 peptide were generated by PCR amplifying the 
corresponding coding regions without the signal sequences from B. 
burgdorferi genomic DNA using primer pairs P1 and P2 (OspC), P3 and P4 
(BmpA) or P5 and P6 (VlsE C6) engineered with BamHI or SalI restriction 
sites (Table 1) and Phusion polymerase (New England Biolabs, Ipswich, MA). 
PCR products were purified (Qiagen, Valencia, CA), digested with restriction 
enzymes (New England Biolabs, Ipswich, MA) and cloned into BamHI/SalI-
digested pGEX-6P-1 (GE Healthcare, Piscataway, NJ) to generate 
translational fusions with GST at the N-terminus. Subsequent clones were 
selected and sequence confirmed by dideoxy sequencing. Hemagglutinin 
(OspC) and C-Myc (BmpA) tags were included at the C-terminus for 
determination of protein purity by immunoblot. pGEX-6P-1 plasmids carrying 
ospC, bmpA or vlsE c6 were transformed into a BL21 strain of E. coli 
(Novagen, Billerica, MA). Protein expression and purification were performed 
according to the procedures outlined in the Bulk GST Purification Module (GE 
Health Sciences, Piscataway, NJ).  
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Table 1. iPCR DNA oligonucleotide sequences used in this study 
Oligo 
number Oligo ID Sequence (5’-3’)a 
   
T1 Template 1 (IgG coupled) BIOTIN-agcctcagaccaagccagacaactgcctcgtgacgttgctgcccctaccaacgtacccctacgagtcc 
T1F Template 1 Forward agcctcagaccaagccagac 
T1R Template 1 Reverse ggactcgtaggggtacgttgg 
T1P Template 1 Probe FAM-actgcctcgtgacgttgctgcccct-BHQ1  
T2 Template 2 (IgM coupled) BIOTIN-aggaggagggtcaagtcaccaacgctgctccaggccatcgtgctgatctggaccctggatcgagtga 
T2F Template 2 Forward aggaggagggtcaagtcacc 
T2R Template 2 Reverse tcactcgatccagggtccag 
T2P Template 2 Probe MAX-acgctgctccaggccatcgtgctga-BHQ1 
P1 OspC partial HA F CGGGATCCCATATGtgtaataattcagggaaagatgg 
P2 OspC HA R ACGCGTCGACttaCGCATAATCCGGCACATCATACGGATAaggtttttttggactttctgc 
P3 BmpA partial myc F CGGGATCCCATatgtgtagtggtaaaggtagtcttg 
P4 BmpA myc R ACGCGTCGACttaCAGATCTTCTTCAGAAATAAGTTTTTGTTCaataaattctttaagaaacttctcataac 
P5 C6 Bb F CGGGATCCCATatgaagaaggatgatcagattg 
P6 C6 Bb R ACGCGTCGACttacttcacagcaaactttccatc 
   
a Uppercase letters indicate non-template sequence used for addition of terminal restriction sites and/or epitope tags. BHQ1, 
black hole quencher 1.  
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iPCR Reagent Preparation 
iPCR assays were assembled as two-sided (sandwich) as detailed in 
Figure 4 for both host antibody (A and B) and spirochete capture (C). Whole 
cell lysate used for immunoblot analysis (preparation described above) and 
GST-fusion recombinant antigens were used to coat magnetic beads for host 
antibody capture using Dynabeads Antibody Coupling Kit (Invitrogen, 
Carlsbad, CA). Bead coupling reactions were performed overnight according 
to the manufacturer’s protocol using 20-30 g antigen(s) per mg Dynabeads 
M-270 Epoxy. The primary antibody used for spirochete capture consisted of 
protein A purified anti-B. burgdorferi polyclonal antibody raised in rabbits 
against whole cell preparations of B. burgdorferi clone B31 ATCC #35210 
(Acris Antibodies, San Diego, CA) and was coupled to magnetic beads as 
described above. Protein coated beads were stored at 4C. The streptavidin 
conjugated reporter antibodies were prepared using the Lightning-Link 
Streptavidin Conjugation Kit (Innova Biosciences, Cambridge, United 
Kingdom) using polyclonal anti-B. burgdorferi (Acris Antibodies, San Diego, 
CA), goat anti-mouse IgM/IgG (Sigma-Aldrich, St. Louis, MO), goat anti-
human IgG (Invitrogen,  
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Figure 4. Schematic representation of iPCR assay for detection of Lyme 
disease biomarkers. (A) Intact spirochete or (B) recombinant protein antigen 
coupled to magnetic beads was used to capture B. burgdorferi-specific host 
generated antibodies. A biotinylated DNA oligonucleotide reporter molecule 
coupled to a streptavidin conjugated reporter antibody was amplified by qPCR 
for detection and quantification. (C) Anti-B. burgdorferi antibody coupled to 
magnetic beads was used for spirochete capture with detection accomplished 
by qPCR amplification of the DNA oligonucleotide coupled reporter antibody 
similar to detection of host antibody. 
Carlsbad, CA) or goat-anti-human IgM (Invitrogen, Carlsbad, CA) 
according to manufacturer’s protocols using an overnight incubation. 
Following conjugation, 10 l of streptavidin labeled antibody was diluted 1:50 
in TBST and 100 nM of single stranded biotin-labeled oligonucleotide 
template was added and the mixture rotated at room temperature for 30 
minutes for antibody-oligo conjugation. Oligonucleotide sequences T1 (IgG 
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coupled) and T2 (IgM coupled) used for tagging are listed in Table 1. The 
oligonucleotide linked streptavidin conjugated antibody was then diluted to a 
1:100 working stock (1:5000 final dilution) and stored at 4C. 
iPCR assay 
Following reagent preparation, 10 l of antigen or antibody coated 
magnetic beads were incubated in 500 l TBST for 30 minutes at 25C on a 
rotator. Following preliminary washing, beads were resuspended in 500 l 
TBST and 5 l serum (mouse or human), 10 l spirochetes suspended in HN 
buffer or blood (1x108-1x104/ml B. burgdorferi B31 A3) or no serum/spirochete 
(negative control) and incubated at 25C rotating for 30 minutes. Beads were 
subsequently washed and resuspended in 300 l TBST with the addition of 
100 l each of IgG and IgM diluted (1:5000) biotinylated oligonucleotide 
streptavidin coupled reporter antibody (anti-mouse IgM/IgG, anti-human IgG, 
anti-human IgM or anti-B. burgdorferi) and incubated at 25C rotating for 30 
minutes. Following assembly of the immune complex, beads were washed 
three times with 900 l TBST followed by magnetic bead capture. Washed 
immune complex coupled beads were resuspended in 20 l TBST for 
subsequent PCR amplification. 
Signal Amplification by Real-Time PCR 
To amplify the signal of the immune complex, real-time PCR was 
performed using an Applied Biosystems 7900 HT (Life Technologies, Grand 
Island, NY) and IQ Supermix (Bio-Rad, Hercules, CA) supplemented with 
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synthetic primers and probes T1F/T1R/T1P (IgG detection) or T2F/T2R/T2P 
(IgM detection) (Table 1). Duplicate reactions were prepared in 20 l volumes 
containing 5 l of iPCR assay processed beads as template, 10 l of 2X 
reaction mix, 0.2 M each primer and 0.4 M fluorophore labeled probe. 
Cycle parameters included a preliminary denaturation (95°C, 20 sec), followed 
by 40 cycles of denaturation (95°C, 1 sec) and annealing/extension (60°C, 20 
sec). The fluorescent signal was collected at the FAM wavelength for IgG 
reactions and MAX wavelength for IgM reactions. The quantification cycle 
(Cq) for each reaction was determined using automatic baseline and 
threshold settings. The average and standard deviation for uninfected/healthy 
samples were used to determine the background level of amplification as is 
commonly observed for iPCR protocols. Positive threshold values were 
established at three times the standard deviation for background levels.  
Human Sera 
Retrospective, de-identified human Lyme disease and healthy control 
serum samples were kindly supplied by Dr. Martin Schriefer (Centers for 
Disease Control and Prevention, Fort Collins, CO). Patient sera were 
collected from 18 Lyme disease patients from endemic Lyme disease regions 
upon initial visit to a physician and 10 days post-initial visit (n = 36). According 
to the CDC’s 2-tiered serological analysis of the samples, 5 of the patients 
were 2-tiered positive at both the initial and follow-up time points, 3 of the 
patients were 2-tiered negative a both time points and 10 of the patients were 
2-tiered negative at the initial visit but 2-tiered positive 10 days later. Human 
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control samples consisted of sera collected from healthy blood donors living in 
non-Lyme endemic areas (n = 5).  
Statistical Analysis 
Spearman rank correlation analyses were performed using GraphPad 
Prism, version 5.0. 
Results 
 
iPCR Using Intact Spirochetes Provided Earlier Detection of Host Response 
Compared to Immunoblot and C6 ELISA in a Murine Model  
The general approach for detection of a host antibody immune 
response by immunoassay is to use sonicated or otherwise disrupted 
organisms to generate protein antigens for antibody capture and subsequent 
detection. However, we hypothesized that this approach may have limited 
success for effectively capturing anti-B. burgdorferi antibodies in 
experimentally infected mouse sera as the majority of the B. burgdorferi 
proteins in the total cell lysate are not likely to be immunogenic. Although B. 
burgdorferi lysate is known to harbor antigenic proteins recognized by mouse 
and human immune sera, these proteins represent a small percentage of the 
total proteins in the lysate and therefore may not provide improved sensitivity 
of detection of an immune response to B. burgdorferi infection. In an effort to 
develop a sensitive, objective method for detection of host antibodies against 
B. burgdorferi antigens, magnetic beads were coated with a polyclonal anti-B. 
burgdorferi Antibody in order to capture formalin fixed intact spirochetes, 
resulting in the generation of magnetic beads coated with intact spirochetes 
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(Figure 5). We predicted that this strategy would result in magnetic beads 
coated in an enriched pool of spirochete antigenic outer surface proteins 
capable of interacting specifically with host antibodies produced in response 
to a B. burgdorferi infection. The sensitivity of iPCR using intact spirochetes to 
capture host antibodies was compared to pre-existing diagnostic methods 
including a commercial C6 ELISA and immunoblot using an in vivo murine 
model. iPCR resulted in the earliest objective detection of a positive infection 
on day 11 post-inoculation (Figure 6A). In comparison, C6 ELISA and 
immunoblot exhibited positive detection of anti-B. burgdorferi antibodies at 
day 14 and day 21 post-inoculation, respectively (Figure 6B and 6C). The 
approximate molecular weights of the immunodominant proteins detected on 
the immunoblot included 18 kilodaltons (kDa), 23 kDa, 33 kDa, 39 kDa and 66 
kDa, which are consistent with the sizes of the bands typically present on a 
Lyme disease diagnostic immunoblot [99, 110]. Uninfected mouse serum was 
negative by all three methods at all time points tested (Figure 6). 
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Figure 5. B. burgdorferi captured on magnetic beads provides a reagent for 
host antibody detection by iPCR. Phase contrast and fluorescent microscopy 
at 510 nm (GFP) and 400x magnification (400x) was used to determine 
capture of formalin fixed B. burgdorferi expressing green fluorescent protein 
on beads coated with anti-B. burgdorferi polyclonal antibodies (top panels) or 
uncoated beads (bottom panels). 
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Figure 6. iPCR demonstrated earlier detection of host response antibodies in 
B. burgdorferi infected mice compared to C6 ELISA and immunoblot. Mouse 
sera were collected prior to inoculation (pre), at specific days post-intradermal 
inoculation with 1x105 B. burgdorferi B31 A3 (left panels), or from uninfected 
mice (right panels) over the course of 21 days. (A) Undiluted sera were 
analyzed for detection of B. burgdorferi IgG antibodies using iPCR. Closed 
system, real time PCR of the DNA reporter molecule was performed using a 
Taqman-based fluorescent probe assay. The mean quantification cycle (Cq) 
background signal, determined using uninfected sera plus three standard 
deviations was designated as the call threshold for a positive detection event 
and indicated here as ∆Cq = 0. Data are shown as the Cq value for each 
sample minus the mean background Cq plus three standard deviations (∆Cq). 
Each data point represents the average of three mice and the standard 
deviation between samples is shown. (B) C6 ELISA (Immunetics, Inc., 
Boston, MA) was performed according to the manufacturer’s instructions with 
the exception that the secondary antibody was peroxidase-conjugated goat 
anti-mouse IgM/IgG (1:5000). The threshold absorbance for the test is 
indicated (horizontal broken line). Each point represents the average of three 
mice and the standard deviation between samples is shown. (C) Total B. 
burgdorferi sonicate was separated by SDS-PAGE and analyzed by IgM/IgG 
immunoblot using immune and pre-immune mouse sera diluted 1:200. The 
positions of the protein standards depict molecular weights in kilodaltons 
(kDa). Data are representative of three mice analyzed. 
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iPCR Using Recombinant GST-OspC and GST-BmpA Provided 
Improved Sensitivity of Detection of Murine Host Antibodies 
Although beads coated with intact in vitro grown spirochetes provided 
early detection of anti-B. burgdorferi antibodies as compared to the C6 ELISA 
and immunoblot (Figure 6), we hypothesized that specific recombinant 
antigens known to be actively expressed during murine infection could 
potentially result in a more sensitive approach. Known B. burgdorferi in vivo-
expressed antigens OspC and BmpA [111] were produced and purified as 
recombinant N-terminal GST-tagged fusion proteins in E. coli. Magnetic beads 
coated with either recombinant protein were used to capture host antibodies 
generated against OspC or BmpA, respectively, and IgM and IgG antibodies 
against each protein were individually quantitated using our iPCR assay. 
GST-OspC coated beads resulted in a marked increase in detection of host 
antibodies starting at day 7 post inoculation for both IgG and IgM (Figure 7A) 
with a gradual decrease in IgM back to baseline by day 21 and a minimal 
decrease in IgG signal to the same time point. GST-OspC-coated beads 
provided a dramatic increase in the level of IgG detection (Cq = 10) as 
compared to the level of iPCR detection of host antibodies using intact 
spirochete-coated beads (Cq = 2.5). GST-BmpA-coated beads provided 
robust positive detection of IgG antibodies beginning at day 9 followed by a 
minimal decrease in the detection signal out to day 21 (Figure 7B). IgM 
antibodies directed against BmpA demonstrated a slight increase in signal 
over the 21-day time course of infection but were not significantly detected 
above background, suggesting that BmpA does not elicit a serodiagnostic IgM 
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response. Together these data suggest that the use of magnetic beads 
coated with specific recombinant B. burgdorferi in vivo-expressed antigens 
results in robust iPCR detection of a humoral response in mice experimentally 
infected with B. burgdorferi and development of an iPCR assay that 
quantitates the host response to multiple B. burgdorferi antigens may result in 
an improved diagnostic method.  
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Figure 7. iPCR using recombinant antigens OspC and BmpA provided 
enhanced detection sensitivity for both IgG and IgM isotypes in a murine 
model of infection. Magnetic beads coated with either purified recombinant 
GST-OspC (A) or GST-BmpA (B) protein were used to capture host response 
antibodies from pre-immune (pre) or post-immune mouse sera collected over 
a time period of 21 days. IgM- and IgG-specific reporter antibody-DNA 
conjugates detected anti-B. burgdorferi antibodies captured by each set of 
antigen coated beads. The IgM (gray bars) and IgG (white bars) response to 
each antigen was determined for each mouse by multiplex quantitative PCR 
using distinct probes specific for the IgM- and IgG-specific DNA reporters 
molecules. The mean quantification cycle (Cq) background signal, determined 
using uninfected sera plus three standard deviations was designated as the 
call threshold for a positive detection event and indicated here as ∆Cq = 0. 
Data are shown as the Cq value for each sample minus the mean background 
Cq plus three standard deviations (∆Cq). Each data point represents the 
average of two mice and the standard deviation between samples is shown. 
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iPCR Demonstrated a Strong Correlation with a Commercial ELISA for 
Detection of Host Antibodies in Human Serum Using the VlsE C6 Peptide 
As recommended by the CDC, the first step of two-tier testing for Lyme 
disease is the use of a sensitive enzyme immunoassay. Although a number of 
commercial kits exist for testing, the C6 peptide of the VlsE locus has been 
shown to be a sensitive and effective predictor for follow-up testing by 
immunoblot and is available as a commercial testing kit. In order to directly 
compare the ability of our iPCR assay to detect human antibodies produced 
against the VlsE C6 peptide with that of an FDA-approved C6 antibody 
detection method, a panel of human serum samples that consisted of samples 
from 18 individuals collected at both an initial visit to the clinic and a ten day 
follow up appointment (n = 36) along with sera collected from 5 healthy 
patients from non-Lyme endemic areas were analyzed by iPCR and using the 
C6 Lyme ELISA (Immunetics, Inc., Boston, MA). iPCR detection of C6-
specific host antibodies demonstrated a strong correlation with that of the 
commercial C6 ELISA (rs = 0. 895, P < 0.0001) (Figure 8). The iPCR assay 
differed from the C6 ELISA in that the iPCR assay provided a separate 
measurement of C6 IgM and C6 IgG antibodies as opposed to the C6 ELISA, 
which quantitated a combined value for both C6 IgM and C6 IgG antibodies. 
Therefore, the iPCR result was considered positive if C6 IgM and/or C6 IgG 
antibodies were detected at or above the established call threshold. All 21 
samples that demonstrated a positive result by the C6 ELISA were also 
positive according to C6 iPCR (Figure 8). Of the four samples determined to 
be equivocal by the C6 ELISA, three of the sera were found to be negative by 
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C6 iPCR; whereas, one sample tested positive for IgM using this method. 
Furthermore, of the 11 serum samples that tested negative by C6 ELISA, five 
of those sera resulted in positive detection of IgM by C6 iPCR. Of note, all 
iPCR positive samples in this group had ∆Cq values of 1 or below. All serum 
samples collected from known healthy individuals tested negative by both C6 
ELISA and C6 iPCR. Together these results suggested that iPCR may have 
improved ability to detect host antibodies to the VlsE C6 peptide compared to 
a current commercial method. 
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Figure 8. Recombinant antigen iPCR successfully quantified B. burgdorferi 
VlsE C6 peptide antibodies in human serum samples. Results for 36 serum 
samples from 18 Lyme disease patients collected upon initial visit to a clinic 
and at a 10 day follow up visit and 5 healthy controls using a multiplex iPCR 
protocol to quantitate both IgM (gray bars) and IgG (white bars) isotypes using 
recombinant B. burgdorferi VlsE C6 peptide coated magnetic beads. A call 
threshold (∆Cq = 0) was assigned at greater than or equal to three standard 
deviations above the mean background signal determined using serum from 
healthy individuals. Serum samples were also tested using a commercial C6 
ELISA (Immunetics, Boston, MA) (diamonds), which was performed according 
to manufacturer protocol with a call threshold for an absorbance (450 nm) of 
1.1 used according to the manufacturer’s protocol. The C6 ELISA value 
represents combined measurement of C6 IgM and IgG antibodies. The patient 
data (1-36) are grouped into three categories: positive, equivocal (equiv) and 
negative according to the C6 ELISA values. Samples H1-H5 correspond to 
the sera collected from the healthy controls and are grouped accordingly 
(healthy). The calculated Spearman rank correlation (rs) was 0.734 (P < 
0.0001) for C6 iPCR IgM versus C6, 0.826 (P < 0.0001) for C6 iPCR IgG 
versus C6, and 0.895 (P < 0.0001) for C6 iPCR IgM and/or IgG versus C6. 
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iPCR Directly Detected B. burgdorferi in Blood 
The demonstrated power of iPCR to detect ultra-low protein levels 
[120] suggests that this method may be a promising tool for direct detection of 
B. burgdorferi in clinical samples. iPCR was shown to be successful for 
capture of live B. burgdorferi using magnetic beads coated with polyclonal 
anti-B. burgdorferi antibodies (Figure 5). This finding suggested the potential 
for iPCR to directly quantitate spirochetes from within patient samples. To test 
the sensitivity of iPCR detection of spirochetes, in vitro grown B. burgdorferi 
were serially diluted in HN buffer (106-102 spirochetes). iPCR detection of 
spirochetes demonstrated a robust dilution curve and a level of detection of 
less than 1,000 organisms (Figure 9A). Detection of in vitro grown B. 
burgdorferi spiked into whole uninfected mouse blood resulted in a ten-fold 
lower limit of detection of 10,000 spirochetes (data not shown), suggesting 
that components of the blood may have an inhibitory effect on the function of 
the iPCR assay. To correlate the sensitivity of iPCR detection of spirochetes 
in blood with quantitation of the number of spirochetes present in the blood of 
infected mice, cohorts of mice were infected with 1x105 B. burgdorferi B31 A3 
and blood samples collected every 24 hours for a period of fourteen days. The 
number of spirochetes/ml of blood, as determined by cfu counts on solid 
medium, were found to increase over the first week of infection and reached a 
peak number of approximately 2,500 spirochetes/ml of blood on day 8 post-
inoculation (Figure 9B). The B. burgdorferi colonies that grew out of the 
infected blood within the solid BSK medium demonstrated morphology and 
growth pattern similar to what is typically observed for spirochete colonies 
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derived from in vitro grown cultures (data not shown). Together, these data 
suggest that although iPCR is a promising method for direct detection of 
spirochetes in B. burgdorferi infected samples, the sensitivity of the method is 
currently below the required level of detection. 
 
Figure 9. iPCR has the potential to directly detect B. burgdorferi in infected 
samples. (A) Live spirochetes were serially diluted in HN buffer (106-102 
spirochetes) and tested in triplicate using iPCR to detect organism capture 
using anti-B. burgdorferi antibody coated magnetic beads. A call threshold 
was assigned at greater than or equal to five times the standard deviation (Cq 
= 30, vertical broken line) above the mean background signal, as determined 
using HN buffer alone (unspiked). PCR non-template controls (NTCs) 
included water and TBST used during the iPCR protocol. (B) Six mice were 
prebled (pre) and inoculated intradermally with 1x105 B. burgdorferi strain B31 
A3. Approximately 50 µl of blood/mouse was collected every day from groups 
of two mice every three days over a time period of 14 days. Blood collected 
from each mouse was plated in solid medium using 50 µl of blood and 
supplemented with a Borrelia antibiotic cocktail (see Materials and Methods 
for details) and the number of colony forming units (cfus) per ml of blood 
determined. Data shown are the average cfus/ml for the two mice sampled at 
each time point. 
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Discussion 
There is a critical need for development of innovative methods for 
improved diagnosis of Lyme disease. Because of its immunological specificity, 
signal amplification power and potential for high-throughput automation, iPCR 
is a strong candidate for development of a robust method to overcome the 
challenges of Lyme diagnosis. We have demonstrated the first application of 
iPCR for detection of host antibodies against B. burgdorferi in both a murine 
model and human sera. 
iPCR Using Recombinant B. Burgdorferi in Vivo-Expressed 
Antigens Is a Sensitive Method for Detection of Host 
Response Antibodies in Infected Mice 
An iPCR assay that incorporated attachment of intact spirochetes to 
magnetic beads provided approximately equivalent sensitivity to current 
diagnostic methods including C6 ELISA and immunoblot when tested in a 
murine model. However, it is well known that B. burgdorferi can alter its 
surface protein expression based on its environment [137-139]. These data 
have led to the conclusion that in vitro grown spirochetes likely do not present 
equivalent amounts and types of surface proteins as would be encountered by 
the host immune system in an active B. burgdorferi infection and suggest that 
the use of multiple in vivo-expressed recombinant antigens may improve 
assay sensitivity [140]. 
B. burgdorferi has been shown to express a number of antigens during 
an active infection that can be utilized as recombinant antigens including 
OspC [141], BmpA [142] to detect host antibodies against B. burgdorferi [99]. 
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We hypothesized that saturating the magnetic beads with recombinant in vivo-
expressed antigenic proteins would provide more binding targets and hence 
higher sensitivity than intact spirochetes. This was evident in the fact that 
active infection was detected on day 7-9 post-inoculation using recombinant 
antigen coated beads as compared to day 11 using intact spirochete coated 
beads and with a stronger signal above background, ∆Cq =5-10 compared to 
∆Cq = 2.5, respectively. This approach also provides the opportunity to utilize 
multiple specific antigens either in a combined or individual assay that can be 
objectively quantified by qPCR.  
Recombinant Antigen iPCR Successfully Quantified B. burgdorferi 
VlsE C6 Peptide Antibodies in Human Serum Samples 
The immunodominant C6 peptide domain of the VlsE protein has 
proven successful as a diagnostic antigen [143] and has become a popular 
choice for first-tier testing prior to follow-up immunoblot testing [144]. An iPCR 
assay employing a recombinant C6 peptide was developed and compared to 
an existing commercial kit that uses the same antigen. iPCR detection of C6 
antibodies in human sera demonstrated a strong correlation with that of the 
commercial C6 Lyme ELISA. The C6 ELISA assay results in a combined 
score for detection of both IgG and IgM isotypes. To provide an additional 
level of discrimination, the iPCR protocol separately quantitates IgG and IgM 
antibodies using distinct qPCR template tags and fluorophores, resulting in an 
individual IgG and IgM iPCR score for each serum sample. All C6 ELISA 
positive sera were found to be positive for IgG and/or IgM C6 antibodies by 
iPCR. The added ability of the iPCR assay to differentially quantitate antibody 
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isotypes for a specific antigen of interest in a single sample may provide 
important information regarding the disease stage at the time of testing, as 
IgM is typically produced early in infection with IgG produced later and for 
longer durations [99, 109]. 
Of the serum samples that were found to be equivocal or negative by 
C6 ELISA, a subset of samples in each category was found to be positive by 
the C6 iPCR assay. These results imply that the iPCR assay may have 
increased sensitivity of detection over the C6 ELISA; however, further 
analysis of a larger serum panel is required to fully support this finding. Serum 
samples from “healthy” individuals with no known exposure to B. burgdorferi 
tested negative by both C6 ELISA and iPCR, suggesting equivalent specificity 
for the two methods. However, considering the small sample size (n = 5), 
additional samples need to be tested to confirm this result. 
iPCR Has the Potential for Direct Detection 
of Spirochetes in Infected Samples 
In an effort to test applicability of iPCR for direct detection of 
spirochetes within a sample, it was determined that 1,000 spirochetes were 
needed in buffer and 10,000 organisms where needed in blood. In the murine 
model used for development of the protocol, the maximum spirochete load in 
blood was measured to be approximately 2,500 spirochetes/ml. Therefore the 
current protocol is unable to directly detect spirochetes during an active 
murine infection. It has been estimated that the average number of cultivable 
B. burgdorferi cells per ml of whole blood in humans is approximately 0.1 
spirochetes per ml and therefore re-isolation of spirochetes from blood has 
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demonstrated limited efficacy when using small volumes of blood [145]. 
Hence, an alternative approach has been proposed to sample blood cultures 
and test by qPCR for increasing amounts of spirochete DNA [146]. While an 
enrichment step is practical, the use of qPCR has the potential to introduce 
false positive results from contaminating B. burgdorferi template DNA in the 
laboratory and typically requires additional protocol steps for nucleic acid 
purification. iPCR, which herein has demonstrated successful detection of 
spirochetes directly from whole blood and is much less prone to the same 
contamination issues as the PCR template is unrelated to B. burgdorferi and 
human DNA, could effectively be used to make a more rapid diagnosis from 
B. burgdorferi infected blood cultures. Future work will focus on improving the 
limit of iPCR direct detection of spirochetes in blood to achieve a detection 
sensitivity of 1-10 organisms, as has been demonstrated for other microbial 
pathogens [122, 147-149]. Furthermore, as B. burgdorferi is transiently 
present in the blood of infected patients the iPCR method may also be 
adapted for direct detection of spirochetes in synovial fluid and/or cerebral 
spinal fluid. Direct detection of spirochetes in patient samples is not 
anticipated to serve as the sole method for diagnosis of Lyme disease, rather 
in conjunction with sensitive and specific detection of B. burgdorferi 
antibodies. 
Contributions of an iPCR-Based Approach Using Recombinant 
Antigens to Future Automated Lyme Disease Diagnostics 
The field of Lyme disease diagnostics is challenged by two main 
issues, a lack of consistent reagents and the need for a more simplified 
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objective form of testing [111]. There are currently multiple commercial assays 
that use a range of antigen types from single recombinant antigens to multiple 
antigens to whole sonicated organisms. One principal focus for the field has 
been on the use of purified, recombinant, or synthetic peptides as the source 
of antigens in immunoassays [111]. Unfortunately, no single antigen has 
demonstrated sufficient sensitivity and specificity to warrant replacing two-tier 
testing [111]. Protein expression differences among species and temporal 
appearance of relevant antibodies to different antigens at various stages of 
Lyme disease make the choice of a single antigen a difficult task and makes 
the combined use of antigens an attractive alternative [111]. The results 
presented here suggest that iPCR combined with the use of recombinant B. 
burgdorferi in vivo-expressed antigens has the potential to provide improved 
sensitivity of detection in an objective format that can be used to detect 
multiple host response antibodies and isotypes. Moreover, future translation 
of this method to an automated point-of-care platform will allow for objective 
routine testing of Lyme disease patients. 
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CHAPTER THREE: 
SIMPLE QUANTITATIVE DETECTION OF HUMAN LYME DISEASE 
INFECTION USING IMMUNO-PCR DETECTION OF 
HOST GENERATED IgG ANTIBODIES AGAINST 
A SINGLE HYBRID RECOMBINANT ANTIGEN 
Introduction 
Lyme disease is the most commonly reported tick-borne illness in the 
United States with approximately 30,000 cases reported to the Centers for 
Disease Control and Prevention (CDC) each year [12].  New preliminary 
estimates released by the CDC indicate that the number of Americans 
diagnosed with Lyme disease each year is closer to 300,000, which are 
roughly 10 times higher than the annual number reported [13].  This new 
estimate supports studies published in the 1990s indicating that the true 
number of cases is between 3- and 12-fold higher than the number of 
reported cases [150, 151] making Lyme disease a significant health concern 
within the United States.  Accurate diagnosis provides a significant obstacle 
for the clinical management of the disease and is necessary to differentiate 
Lyme disease from other diseases with similar clinical presentation.  
Misdiagnosis of Lyme disease is common due to difficulties in detection of 
Borrelia burgdorferi, the causative agent of Lyme disease [152].  Although a 
wide range of laboratory diagnostic approaches have been explored, the 
current accepted method utilizes detection of serological response to B. 
burgdorferi antigens [114]. 
The current method for detection of Lyme disease in a clinical setting 
approved by the CDC entails a two-tiered approach using a first-tier enzyme 
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immunoassay (ELISA) followed by a second-tier immunoblot assay for both 
IgM and IgG B. burgdorferi-specific antibodies using whole cell B. burgdorferi 
lysates, recombinant antigens, or various combinations depending on the 
commercial kit used [111].  The ELISA provides a quantitative and sensitive 
first-tier screen but lacks the specificity and broad strain applicability [153] 
required for a standalone test.  The second-tier immunoblot provides a higher 
level of specificity but currently requires somewhat subjective analysis due to 
its qualitative nature and lack of automation [154].  A tiered approach has to 
date provided the most effective means of diagnosing Lyme disease in a 
clinical setting [111]. 
Other approaches to diagnosing Lyme disease have been developed 
including live culture, PCR and additional molecular based methods with no 
technique surpassing the effectiveness of a serology based approach [111].  
In our previous study we demonstrated the use of immuno-PCR (iPCR) for 
detection of host generated antibodies in a murine model as well as 
preliminary data using serum collected from Lyme disease patients and 
healthy controls [155].  Our results indicated that iPCR using B. burgdorferi 
whole cell sonicates and a limited number of B. burgdorferi recombinant 
antigens provided higher sensitivity of detection of B. burgdorferi antibodies in 
infected mice and equivalent sensitivity of detection of B. burgdorferi 
antibodies in Lyme patient serum compared to both ELISA and immunoblot 
[155]. 
It is well established that multiple antigens are required for accurate 
overall diagnosis of the multiple stages and types of Lyme disease [111].  
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Furthermore, it is critical that the antigens used for diagnosis are 
demonstrated to have low cross-reactivity for diseases other than Lyme 
disease.  The goals of this study were to 1) determine the range of the levels 
of background detection of the Lyme disease iPCR assay across a healthy 
human population, 2) explore a larger subset of antigens for increased 
sensitivity and specificity and 3) compare the performance of the optimized 
Lyme disease iPCR protocol with the current 2-tier method of Lyme disease 
diagnosis. 
Materials and Methods 
 
Healthy Human Sera 
The current study was approved by University of Central Florida’s 
Institutional Review Board (UCF IRB; FWA00000351, IRB00001138). All 
procedures and investigators involved in the sample collection process were 
UCF IRB-approved with Collaborative Institutional Training Initiative training.  
All donors provided written consent to participate in the current study.  Sample 
collection was undertaken at the UCF campus.  UCF is a diverse community 
of nearly 60,000 students and approximately 8,000 faculty and staff members 
of various ages, ethnic and racial backgrounds.  Individuals were classified for 
inclusion in the study if they had not been previously diagnosed with Lyme 
disease, received a Lyme vaccine or lived within the past 10 years in a state 
with a high incidence of Lyme disease (Connecticut, Delaware, Maine, 
Maryland, Massachusetts, Minnesota, New Hampshire, New Jersey, New 
York, Pennsylvania, Vermont, Virginia and Wisconsin). Approximately 10 
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millilitres of blood were sampled according to the IRB approved protocol from 
36 individuals into serum separator tubes, inverted five times to mix the clot 
activator with the blood and allowed to clot for at least 30 minutes.  Serum 
fractions were collected by centrifugation at 1200 x g for 10 minutes.  Serum 
was further clarified by centrifugation at 9100g for 5 minutes to remove any 
insoluble material and stored at 4°C for short term or -80°C for long term 
storage.  
 Lyme Disease Human Sera Panel 
Retrospective, human Lyme disease and healthy control serum 
samples were kindly supplied by Dr. Martin Schriefer (Centers for Disease 
Control and Prevention, Fort Collins, CO).  The CDC Research Panel I 
consisted of patient sera collected from 32 individuals including patients with 
stage 1, 2 or 3 Lyme disease (n=12), look-alike diseases including 
fibromyalgia, rheumatoid arthritis, multiple sclerosis, mononucleosis, syphilis 
and severe periodontitis (n=12) and healthy individuals from both Lyme 
disease endemic (n=4) and non-endemic (n=4) areas.  All Lyme disease 
samples were confirmed B. burgdorferi culture and PCR positive.  The blinded 
CDC Research Panel II consisted of patient sera collected from 92 individuals 
including patients with stage 1, 2,or 3 Lyme disease (n=32), look-alike 
diseases including fibromyalgia, rheumatoid arthritis, multiple sclerosis, 
mononucleosis, syphilis and severe periodontitis (n=36) and healthy 
individuals from both Lyme disease endemic (n=12) and non-endemic (n=12) 
areas.  Similar to CDC Research Panel I, all Lyme disease samples in CDC 
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Research Panel II were confirmed B. burgdorferi culture and PCR positive.  
Prior to analysis all serum samples were clarified by centrifugation at 9,100 x 
g for 5 minutes to remove any insoluble material and stored at 4°C. 
Cloning and Expression of Recombinant 
Antigens Lacking GST Fusion Tags 
rGST-BmpA and rGST-OspC were constructed as previously described 
[155].   In frame glutathione-S-transferase (GST) fusion proteins for BBK19, 
OspA, DbpA, RevA, Crasp-2 and BBK50 were generated by PCR amplifying 
the corresponding coding regions without the signal sequences from B. 
burgdorferi genomic DNA using primer pairs 1147 and 1148 (BBK19), 1151 
and 1152 (OspA), 1145 and 1146 (DbpA), 1143 and 1144 (RevA), 1149 and 
1150 (Crasp-2) or 1043 and 1044 (BBK50) engineered with BamHI and SalI 
or XhoI restriction sites (Table 2) and Phusion polymerase (New England 
Biolabs, Ipswich, MA). PCR products were purified (Qiagen, Valencia, CA), 
digested with appropriate restriction enzymes (New England Biolabs, Ipswich, 
MA) and cloned into BamHI and SalI or XhoI-digested pGEX-6P-1 (GE 
Healthcare, Piscataway, NJ) to generate translational fusions with GST at the 
N-terminus.  Subsequent clones were selected and sequence confirmed by 
sequence analysis.  pGEX-6P-1 plasmids carrying bmpA, ospC, bbk19, ospA, 
dbpA, revA, crasp-2 or bbk50 were transformed into a BL21 strain of E. coli 
(Novagen, Billerica, MA). 
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Table 2. iPCR DNA oligonucleotide sequences used in this study 
Oligo 
number Oligo ID Sequence (5’-3’)
a
 
   
T1 Template 1 (IgG coupled) BIOTIN-agcctcagaccaagccagacaactgcctcgtgacgttgctgcccctaccaacgtacccctacgagtcc 
T1F Template 1 Forward agcctcagaccaagccagac 
T1R Template 1 Reverse ggactcgtaggggtacgttgg 
T1P Template 1 Probe FAM-actgcctcgtgacgttgctgcccct-BHQ1  
T2 Template 2 (IgM coupled) BIOTIN-aggaggagggtcaagtcaccaacgctgctccaggccatcgtgctgatctggaccctggatcgagtga 
T2F Template 2 Forward aggaggagggtcaagtcacc 
T2R Template 2 Reverse tcactcgatccagggtccag 
T2P Template 2 Probe MAX-acgctgctccaggccatcgtgctga-BHQ1 
1147 BBK19 F CGGGATCCttttcaaaagattctcgatcacg 
1148 BBK19 R ACGCCTCGAGtcaattgttaggtttttcttttcc 
1151 OspA F CGGGATCCaagcaaaatgttagcagcc 
1152 OspA R ACGCCTCGAGttattttaaagcgtttttaatttcatcaag 
1145 DbpA F CGGGATCCggactaacaggagcaacaa 
1146 DbpA R ACGCCTCGAGttagttatttttgcatttttcatcag 
1143 RevA F CGGGATCCaaagcatatgtagaagaaaagaaag 
1144 RevA R ACGCCTCGAGttaattagtgccctcttcg 
1149 Crasp2 F CGGGATCCgatgttagtagattaaatcagagaaatatt 
1150 Crasp2 R ACGCCTCGAGctataataaagtttgcttaatagctttataag 
1043 BBK50 F CGGGATCCatgtgtaaattatatgaaaagcttacaaataaatcgc 
1044 BBK50R CCGCTCGAGttatctagagtccatatcttgcaattt 
   
1084 DbpA_PEPC10 R AGGTTTTTTTGGACTTTCTGCCACAACAGGgttatttttgcatttttcatcagtaaaagt 
1085 C6_PEPC10 F CCTGTTGTGGCAGAAAGTCCAAAAAAACCTatgaagaaggatgatcagattgc 
1023 C6 Bb R ACGCGTCGACttacttcacagcaaactttccatc 
   
a Uppercase letters indicate non-template sequence used for addition of terminal restriction sites, epitope tags or synthetic 
assembly. 
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Protein expression was induced by growth of BL21 cells containing the 
expression construct for each B. burgdorferi antigen in 50-100 ml Magic 
Media E. coli expression medium according to manufacturer’s protocol 
(Invitrogen, Carlsbad, CA) for 24 hours at 37°C with aeration.  Recombinant 
protein purification was performed according to the procedures outlined in the 
Bulk GST Purification Module (GE Health Sciences, Piscataway, NJ).  Purified 
proteins were dialyzed in Tris buffered saline (50 mM Tris-HCl, 150 mM NaCl, 
pH 7.5) overnight at 4°C using D-tube dialyzers (EMD Millipore Chemicals, 
Philadelphia, PA) and two buffer exchanges to remove excess glutathione.  
Dialyzed proteins were subjected to protease cleavage of the GST tag 
overnight at 4 °C according to procedures outlined in the PreScission 
Protease kit (GE Healthcare, Piscataway, NJ).  Cleaved proteins were purified 
from GST and excess protease using two rounds of Bulk GST purification (GE 
Health Sciences, Piscataway, NJ) and collection of the eluent.  Purified 
proteins lacking a GST tag were concentrated using Amicon Ultra-2 
Centrifugal Filter Devices (EMD Millipore Chemicals, Philadelphia, PA) to a 
volume of approximately 80 µl and stored at 4°C.  Total protein was quantified 
by absorbance spectrophotometry at a wavelength of 280 nm.  Recombinant 
protein purity and seroreactivity was determined by coomassie gel and 
immunoblot using infected mouse serum.  Briefly, 100 nanograms of each 
recombinant protein were separated by 12.5% polyacrylamide gel 
electrophoresis.  For coomassie staining, gels were incubated in Imperial 
Protein Stain (Thermo Scientific, Rockford, IL) for 1 hour and destained in 
deionized water for 1 hour prior to imaging.  For immunoblot analysis proteins 
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were transferred to a nitrocellulose membrane and the membrane was 
blocked in 5% skim milk and incubated for 1 hour with mouse sera collected 3 
weeks post inoculation with wild type B. burgdorferi as previously described 
[155], diluted 1:200 in Tris buffered saline/0.05% tween pH 7.6 (TBST), 
washed twice with TBST, incubated with HRP-conjugated goat anti-mouse 
IgG/IgM (Chemicon International, Billerica, MA) for 1 hour, washed twice with 
TBST and the signal was detected using the SuperSignal West Pico 
Chemiluminescent Substrate Kit (Thermo Scientific, Rockford, IL). 
Cloning and Expression of Recombinant 
DOC Antigen Lacking GST Fusion Tag 
In frame glutathione-S-transferase (GST) fusion protein for the DOC 
hybrid protein was generated using two distinct PCR amplification steps.  
First, the corresponding coding regions for DbpA and the C6 peptide of VlsE 
were amplified separately from B. burgdorferi genomic DNA with non-template 
addition of the PEPC10 sequence to each amplicon using primer pairs 1145 
and 1084 (DbpA-PEPC10) and 1085 and 1023 (C6-PEPC10), respectively, 
engineered with BamHI/SalI restriction sites (Table 2).  Both PCR products 
were diluted 100-fold, combined and synthetically assembled into the DOC 
construct by overlapping PCR using primer pairs 1145 and 1023.  Final 
constructs were sequenced verified and recombinant protein generated and 
purified as described above for the other B. burgdorferi antigens. 
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iPCR Reagents, Assay and Signal Amplification 
iPCR reagents were prepared and assay conducted as previously 
described [155] with minor modifications.  Briefly, iPCR assays were 
assembled in a two-sided (sandwich) manner as detailed in Figure 10A with 
the capability to simultaneously capture and report both IgM and IgG host 
generated antibodies (Figure 10B).  Recombinant antigens lacking fusion tags 
were used to coat magnetic beads for host antibody capture using 10-20 µg of 
antigen per mg of beads.  Beads were resuspended in 500 µl TBST for 
secondary antibody incubation.  Signal amplification by real-time quantitative 
PCR was accomplished as previously described [155] with the quantification 
cycle (Cq) for each reaction determined using manual baseline determination 
(Cycle 10-20) and a manual threshold setting of 1.0. 
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Figure 10. Schematic representation of multiplex iPCR assay for detection of 
Lyme disease host antibodies using recombinant antigens. A recombinant 
protein antigen coupled to magnetic beads was used to capture B. 
burgdorferi-specific host-generated antibodies (A). A biotinylated DNA 
oligonucleotide reporter molecule coupled to a streptavidin-conjugated 
reporter antibody was amplified by qPCR for detection and quantification. (B) 
The same antigen coupled beads were used to simultaneously capture both 
IgM and IgG host generated antibodies which were detected in a multiplex 
fashion using isotype-specific secondary antibodies coupled to unique 
reporter oligonucleotides (T1 and T2) similarly amplified by qPCR for 
quantification. 
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Positive Threshold Value and Statistical Analysis 
Positive threshold values were established for each individual antigen 
using an antigen specific multiplier of the standard deviation (SD) above the 
mean value for a group of sixteen healthy individuals.   The antigen specific 
multiplier was determined using CDC Research Panel I samples as the 
training set.  The antigen specific multiplier was set at a minimal value where 
the samples from all culture positive individuals resulted in a Lyme disease 
iPCR positive ΔCq above background. The coefficient of variation (CV) was 
calculated as the ratio of the SD to the mean.  Sensitivity was calculated as 
the ratio of the number of true positives (correctly identified) to combined true 
positives and false negatives (incorrectly rejected).  Specificity was calculated 
as the ratio of the number of true negatives (correctly rejected) to combined 
true negatives and false positives (incorrectly identified).  Comparisons were 
made using the Fisher exact test.  P values were 2-tailed and a value of <0.05 
was considered significant.  All analyses were conducted using Prism 
GraphPad (GraphPad Software, La Jolla, CA). 
 
Results 
 
IPCR Demonstrates Strong within Assay Precision and Reproducible 
Background across a Sample Population of Healthy Individuals 
We previously demonstrated proof of principle for iPCR detection of 
human host generated B. burgdorferi antibodies using VlsE C6 peptide coated 
magnetic beads and a panel of serum samples (n=36) from Lyme disease 
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positive and Lyme disease negative patients and healthy controls [155].  This 
feasibility study was accomplished using a small number of healthy samples 
(n=5) to establish test efficiency and background threshold levels.  In an effort 
to establish a better understanding of the Lyme disease iPCR assay 
performance, including repeatability and the variability of the background of 
the assay across a healthy population, the number of replicates and overall 
sample size of healthy individuals was expanded.  Prospective blood samples 
were collected from consenting individuals without a history of Lyme disease 
under the approval of the UCF Institutional Review Board.  To assess assay 
repeatability, the serum from a single healthy individual was tested eighteen 
times using the same reagent preparation lots including DbpA antigen coated 
beads and oligo-labeled secondary antibodies.  The results of this analysis 
demonstrated low within assay variability for both the IgM- and IgG-specific 
detection reagents as indicated by standard deviation values for each data set 
of 0.39 and 0.73, respectively and a coefficient of variation values for each 
data set of 1.34% and 2.30%, respectively (Figure 11). 
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Figure 11. Immuno-PCR magnetic bead protocol demonstrates strong within 
assay precision. (A) Serum collected from a single healthy individual was 
assayed 18 times by IgM/IgG multiplex iPCR using recombinant DbpA antigen 
coupled to magnetic beads.  (B) The mean, standard deviation (SD), range 
and coefficient of variation (CV) (calculated as the ratio of SD to Mean) were 
calculated for both IgM and IgG.  Each dot represents a single replicate and 
the horizontal line represents the mean Cq value for all replicates for each 
isotype.  The y-axis represents the quantification cycle (Cq) determined by 
real time quantitative PCR. 
To determine the background variability of the Lyme disease iPCR 
assay across a healthy human population, the sera from 36 healthy 
individuals were tested in duplicate using magnetic beads coated with the 
DbpA antigen and the oligo-labeled IgM and IgG secondary antibodies used 
for the repeatability analysis.  Similar to the within sample repeatability 
analysis, the results of the between sample variability analysis demonstrated 
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a standard deviation across the population of 0.79 for the background 
detection of IgM antibodies and 0.84 for the background detection of IgG 
antibodies and  coefficients of variation of 2.66% and 2.63%, respectively 
(Figure 12). 
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Figure 12. Lyme disease immuno-PCR demonstrates reproducible 
background across a healthy human population for both IgM and IgG isotypes 
using the DbpA antigen.   Sera from 36 healthy individuals were assayed in 
duplicate by multiplex iPCR using both (A) IgM and (B) IgG secondary 
antibodies and recombinant DbpA antigen coupled magnetic beads.  Each dot 
represents a single replicate per individual with a horizontal line representing 
the mean value for duplicate serum samples from each individual.  (C) The 
mean, standard deviation, range and coefficient of variation (calculated as the 
ratio of standard deviation to the mean) is listed for each isotype.  The y-axis 
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represents the quantification cycle (Cq) determined by real time quantitative 
PCR. 
The Mean Background and Standard Deviation Values Across a Population of 
Healthy Individuals are Unique for Each Lyme Disease iPCR Assay 
Antigen/Isotype Combination 
The analysis of the Lyme disease iPCR assay repeatability and 
population variability using DbpA coupled magnetic beads demonstrated that 
the mean background value for the detection of IgM versus IgG antibodies 
differed by as much as ~2.5 Cq (Figure 11 and 12).  Based on this 
observation, we predicted that depending on the different antigen used each 
Lyme disease iPCR assay would each result in a distinct mean background 
Cq value.  If true, this finding would impact the determination of the 
background threshold setting for the assay making it necessary to assign a 
distinct background threshold for each antigen/isotype combination.  To test 
this hypothesis, a panel of 8 recombinant B. burgdorferi antigens either known 
or suspected to be seroreactive in humans [87-90, 92, 93, 96, 97, 102] was 
generated and purified as in-frame N-terminal fusions to GST.  To eliminate 
any possibility of antibody cross reactivity to the GST tag, this sequence was 
proteolytically removed.  The purity and antigenicity of each recombinant 
antigen was demonstrated by SDS-PAGE followed by coomassie brilliant blue 
staining and immunoblot analysis using pooled sera collected from B. 
burgdorferi infected mice (Figure 13). 
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Figure 13. Purified recombinant protein panel exhibits antigenicity in infected 
mouse serum.  Recombinant proteins expressed in E. coli were protease 
treated to remove the GST fusion tag followed by subsequent purification to 
remove residual GST and protease. Purity and seroreactivity was determined 
by (A) coomassie gel and (B) immunoblot using infected mouse serum. 
Each antigen was coupled to magnetic beads and examined by iPCR 
for both IgM and IgG background reactivity across sixteen serum samples 
collected from healthy individuals.  As predicted, all antigen/isotype 
combinations demonstrated unique background values that ranged from a 
mean Cq of 26.09 to 32.46 for IgM and 25.30 to 36.62 for IgG and a standard 
deviation of 0.40 to 1.53 for IgM and 0.37 to 1.47 or IgG (Figure 14).  
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Figure 14. Immuno-PCR demonstrates low intra-antigen background 
variability for an antigen panel across a healthy human population.  Sera from 
16 healthy individuals were assayed by multiplex iPCR for both (A) IgM and 
(B) IgG host generated antibodies against recombinant DbpA, BmpA, OspC, 
BBK19, OspA, RevA, Crasp2 and BBK50 antigen coupled magnetic beads.  
Each dot represents a single individual replicate and the horizontal line 
represents the mean Cq value for all individuals for each antigen/isotype 
combination.  Each antigen mean and standard deviation (SD) are listed.  The 
y-axis represents the quantification cycle (Cq) determined by real-time PCR. 
The population mean, standard deviation (SD), range and coefficient of 
variation (CV) is shown for each antigen/isotype combination. 
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Multiplex iPCR Detection of IgM and/or IgG Host Response Antibodies 
Against B. burgdorferi Using a Panel of Antigens Provides Equivalent 
Sensitivity and Specificity to 2-tier Testing 
Most existing protocols for Lyme disease diagnostics require the use of 
multiple antigens to diagnose the disease.  In an effort to further explore the 
application of iPCR as a Lyme disease diagnostic, we sought to determine a 
similar methodology that utilizes a combination of results for different antigens 
to facilitate diagnosis.  The panel of eight B. burgdorferi antigens was tested 
against the CDC Research Panel I collection of sera using multiplex iPCR for 
simultaneous detection of IgM and IgG host generated antibodies.  The same 
human serum panel had previously been tested according to CDC guidelines 
by commercial ELISA followed by IgM and IgG immunoblot and classified for 
2-tier testing status.  Samples were classified as Lyme disease positive by 
iPCR if they resulted in positive values above the predetermined antigen-
specific threshold for IgM or IgG for one or more of the eight antigens tested.  
Using this criteria iPCR testing provided similar results to 2-tier testing for the 
Lyme disease patient (Table 3) and non-Lyme disease patient (Table 4) 
samples with one exception.  A single early Lyme disease patient sample, 
which was deemed 2-tier negative, tested positive by iPCR (Table 3 sample 
A4).  It should also be noted that no single antigen provided iPCR-positive 
results for all Lyme disease patient samples comprising different stages and 
types of disease. 
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Table 3. iPCR using eight antigens demonstrates equivalent results to 2-tier testing for CDC Research Panel I 
 
a Values shown represent the ΔCq above the positive call threshold Cq value determined using an antigen specific multiplier of 
the SD above the mean value for a set of healthy individuals for each antigen/isotype combination. 
b Blank boxes represent iPCR values below the positive call threshold. 
c 2-tier results established by standard ELISA and IgG/IgM immunoblot 
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Table 4. iPCR data for CDC Research Panel I for eight antigens and the DOC hybrid antigen in duplicate IgM/IgG 
 
a 
Values shown represent the ΔCq above (gray shading) or below (parenthesis) the positive call threshold Cq value determined using an antigen specific 
multiplier of the SD above the mean value for a set of healthy individuals for each antigen/isotype combination. 
b
2-tier results established by standard ELISA and IgG/IgM immunoblot
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Simplified Single Hybrid Antigen iPCR Detection of Host Generated IgG 
Antibodies Alone Confirms 2-tier Results for a Panel of Human 
Serum with Semi-quantitative Determination of Disease Stage 
iPCR testing with the panel of eight B. burgdorferi antigens showed 
strong potential as a Lyme disease diagnostic by reproducing the 2-tier test 
results for CDC Research Panel I samples.  Although successful, the use of 
multiple antigens tested against IgM and IgG increases test complexity by 
requiring testing of a single sample with multiple antigens.  In an effort to 
further simplify the Lyme disease iPCR approach, we theorized that a single 
hybrid antigen composed of the immunogenic epitopes of multiple B. 
burgdorferi antigens would provide similar results to testing with a panel of 
whole individual antigens.  To examine the applicability of a single hybrid 
antigen for iPCR detection of host generated antibodies against B. burgdorferi 
infection, we synthetically constructed a novel hybrid antigen composed of full 
length DbpA, the PEPC10 peptide (OspC) [156] and the C6 peptide (VlsE) 
[157] referred to as the ‘DOC’ antigen (Figure 15A).  Similar to the previous 
eight recombinant antigens, we determined the protein purity and 
seroreactivity toward B. burgdorferi infected mouse sera of the hybrid protein 
(Figure 13).  The range of the background reactivity of the DOC antigen in the 
iPCR assay was determined using the serum from a group of sixteen healthy 
individuals (Figure 15B).  The results of the between sample variability 
analysis demonstrated a standard deviation across the population of 0.57 for 
the background detection of IgM antibodies and 0.51 for the background 
detection of IgG antibodies and coefficients of variation of 2.31% and 1.94%, 
respectively. Using iPCR, we then tested the hybrid antigen in duplicate 
 76 
against the CDC Research Panel I for IgM and IgG reactivity utilizing the 
results to establish a positive call threshold. 
 
Figure 15. Development of a hybrid antigen for simple detection of Lyme 
disease.  The DOC antigen (A) was assembled using full length DbpA protein 
fused to the PEPC10 (OspC) and the C6 (VlsE) peptides and (B) was tested 
by iPCR using DOC coated magnetic beads against sixteen healthy 
individuals for IgM and IgG for the range of the background reactivity. Each 
dot represents a single individual replicate and the horizontal line represents 
the mean Cq value for all individuals for IgM and IgG.  The mean and 
standard deviation (SD) is listed.  The y-axis represents the quantification 
cycle (Cq) determined by real-time quantitative PCR. 
The DOC antigen IgG results confirmed all 2-tier positive results 
(Figure 16B).  Interestingly, the iPCR assay using the DOC antigen tested 
negative for detection of host generated IgM antibodies for all human samples 
analysed (Figure 16A).  
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Figure 16. The iPCR assay using the DOC hybrid antigen provides robust 
detection of Lyme disease. A serum panel composed of 32 samples and 
consisting of Lyme infected individuals both early (acute and convalescent) 
and late (neurologic and  arthritis) stage as well as look-alike diseases and 
healthy individuals from endemic and non-endemic areas was tested in 
duplicate using DOC iPCR for both (A) IgM and (B) IgG reactivity. Each dot 
represents a single individual replicate and the black horizontal lines 
represent the mean Cq value for all individuals within each category.  Filled 
circles represent samples that were 2-tier positive with open circles signifying 
2-tier negative status.  A positive threshold value was established using a 
multiplier of the standard deviation (SD) above the mean value with the ΔCq 
threshold (gray horizontal line) representing a value of zero. 
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Although early and specific detection is the primary goal for any Lyme 
disease diagnostic, determination of the stage of disease progression would 
provide additional information to aide in the treatment of the disease.  It is 
logical to assume that the amount of host-generated B. burgdorferi antibody 
will increase with further disease progression.  Due to the quantitative nature 
of iPCR testing, we hypothesized that the amount of anti-DOC host generated 
IgG antibody would correlate with disease stage.  The mean iPCR value was  
-1.61 ± 0.36 for acute early Lyme disease patients, 0.67 ± 0.38 for 
convalescent early Lyme disease patients and 2.39 ± 0.64 for late Lyme 
disease patients for a total of n=4 samples per group.  These data suggested 
a correlation of increasing anti-DOC antibody with disease progression. 
DOC Hybrid Antigen IgG iPCR Demonstrates Improved Sensitivity 
and Higher Specificity Compared to 2-tier Testing for a 
Blinded Panel of Human Serum Samples 
Initial success of DOC IgG iPCR with replicating 2-tier results for a 
panel of 32 human serum samples provided strong evidence for the 
application of our approach as a simplified Lyme disease diagnostic.  We next 
sought to perform a larger scale blinded validation analysis of our assay.  The 
CDC Research Panel II composed of 92 samples including sera collected 
from early, cardiac, arthritic and neurological Lyme disease patients as well as 
patients with Lyme look-alike diseases and healthy donors was tested by 
iPCR for host generated IgG antibodies to the DOC hybrid antigen and 
compared to 2-tier test results (Table 5). 
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Table 5. iPCR data for CDC Blinded Research Panel II for DOC hybrid antigen IgG 
Sample Sample Group 
DOC 
IgG
a
 
iPCR 
interpretation 
2-Tier 
Interpretation
b
 
EIA 
Interpretation 
IgM WB 
Bands 
IgG WB Bands 
1 Early Lyme-EM 2.24  Pos Pos Pos 41, 39, 23 58, 41, 39, 23, 18 
2 Early Lyme-EM 2.20  Pos Pos Pos 23 66, 45, 41, 39, 23, 18 
3 Early Lyme-EM 2.07  Pos Pos Pos 41, 39, 23 41, 23 
4 Early Lyme-EM 2.05  Pos Pos Pos 41 58, 45, 41, 39, 23, 18 
5 Early Lyme-EM 1.59  Pos Pos Pos 41, 23 41, 23 
6 Early Lyme-EM 1.45  Pos Pos Pos 41, 39, 23 66, 45, 41, 39, 23, 18 
7 Early Lyme-EM 1.08  Pos Pos Pos 41, 39, 23 41, 23 
8 Early Lyme-EM 0.80  Pos Pos Pos 41, 23 41 
9 Early Lyme-EM 0.52  Pos Neg Pos 23 66, 41, 23 
10 Early Lyme-EM 0.08  Pos Neg Equ - - 
11 Early Lyme-EM (0.08) Neg Neg Pos 23 66, 41, 23 
12 Early Lyme-EM (0.27) Neg Neg Neg - 66 
13 Early Lyme-EM (0.58) Neg Neg Pos 23 - 
14 Early Lyme-EM (0.91) Neg Neg Pos 23 41, 23 
15 Early Lyme-EM (1.00) Neg Neg Neg - 67 
16 Early Lyme-EM (1.01) Neg Neg Neg 39, 23 23 
17 Early Lyme-EM (1.22) Neg Neg Neg - 23 
18 Early Lyme-EM (1.48) Neg Neg Equ 23 41 
19 Early Lyme-EM (1.50) Neg Neg Neg 23 - 
20 Early Lyme-EM  1.14  Pos Neg Pos 41 41, 23, 18 
21 Neurologic Lyme 2.64  Pos Pos Pos 41, 23 45, 41, 23 
22 Neurologic Lyme 2.01  Pos Pos Pos 41, 39, 23 41, 39, 23 
23 Neurologic Lyme 0.00  Pos Pos Pos 41, 39, 23 41, 23 
24 Neurologic Lyme (0.26) Neg Neg Neg 41, 23 41, 23 
25 Lyme arthritis 3.44  Pos Pos Pos 23 93, 66, 58, 45, 41, 39, 30, 28, 23, 18 
26 Lyme arthritis 2.96  Pos Pos Pos 41 93, 66, 58, 41, 39, 30, 28, 23, 18 
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Sample Sample Group 
DOC 
IgG
a
 
iPCR 
interpretation 
2-Tier 
Interpretation
b
 
EIA 
Interpretation 
IgM WB 
Bands 
IgG WB Bands 
27 Lyme arthritis 2.67  Pos Pos Pos 41, 23 93, 66, 58, 45, 41, 39, 30, 28, 23, 18 
28 Lyme arthritis 2.62  Pos Pos Pos - 66, 58, 45, 41, 39, 28, 23, 18 
29 Lyme arthritis 2.09  Pos Pos Pos 23 58, 41, 39, 23, 18 
30 Lyme arthritis 1.84  Pos Pos Pos - 93, 66, 58, 41, 39, 30, 23, 18 
31 Cardiac Lyme 2.83  Pos Pos Pos 41, 39, 23 66, 45, 41, 23, 18 
32 Cardiac Lyme 1.37  Pos Pos Pos 41, 39, 23 66, 45, 41, 23, 18 
33 Fibromyalgia (0.28) Neg Neg Neg - 23 
34 Fibromyalgia (0.81) Neg Neg Neg 39 58, 41 
35 Fibromyalgia (1.70) Neg Neg Neg - 41 
36 Fibromyalgia (1.89) Neg Neg Neg - 41 
37 Fibromyalgia (1.93) Neg Neg Neg - - 
38 Fibromyalgia (2.30) Neg Neg Neg - - 
39 Rheumatoid arthritis (0.90) Neg Neg Pos - 41 
40 Rheumatoid arthritis (1.17) Neg Neg Neg - 41 
41 Rheumatoid arthritis (1.56) Neg Neg Neg - - 
42 Rheumatoid arthritis (1.73) Neg Pos Pos 41, 23 - 
43 Rheumatoid arthritis (1.77) Neg Neg Neg - - 
44 Rheumatoid arthritis (2.05) Neg Neg Neg - - 
45 Multiple sclerosis (0.55) Neg Neg Neg 39, 23 41 
46 Multiple sclerosis (0.78) Neg Neg Pos - 41, 23 
47 Multiple sclerosis (1.09) Neg Neg Neg - - 
48 Multiple sclerosis (1.11) Neg Neg Neg 39 - 
49 Multiple sclerosis (1.75) Neg Neg Neg - - 
50 Multiple sclerosis (2.05) Neg Neg Neg - 66 
51 Mononucleosis (0.09) Neg Neg Neg - 39 
52 Mononucleosis (0.28) Neg Neg Pos - 41, 39 
53 Mononucleosis (0.58) Neg Neg Pos - - 
54 Mononucleosis (0.77) Neg Neg Equ - 41 
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Sample Sample Group 
DOC 
IgG
a
 
iPCR 
interpretation 
2-Tier 
Interpretation
b
 
EIA 
Interpretation 
IgM WB 
Bands 
IgG WB Bands 
55 Mononucleosis (0.78) Neg Neg Neg - - 
56 Mononucleosis (1.25) Neg Neg Neg 41, 23 66, 58, 41 
57 Syphilis (0.56) Neg Neg Pos - - 
58 Syphilis (0.75) Neg Neg Pos - 41 
59 Syphilis (0.96) Neg Neg Pos - 41 
60 Syphilis (1.01) Neg Pos Pos 39, 23 - 
61 Syphilis (1.38) Neg Neg Pos - 41 
62 Syphilis (1.47) Neg Neg Neg - - 
63 Severe periodontitis (0.22) Neg Neg Neg - - 
64 Severe periodontitis (0.29) Neg Neg Neg - - 
65 Severe periodontitis (0.56) Neg Neg Neg - - 
66 Severe periodontitis (0.90) Neg Neg Neg - 45, 41 
67 Severe periodontitis (1.03) Neg Neg Neg - 66 
68 Severe periodontitis (3.04) Neg Neg Neg - - 
69 Healthy endemic  0.23  Pos Neg Neg - 23 
70 Healthy endemic  (0.04) Neg Neg Pos 41 66 
71 Healthy endemic  (0.53) Neg Neg Pos - 41, 23 
72 Healthy endemic  (0.87) Neg Neg Neg 23 41 
73 Healthy endemic  (0.87) Neg Neg Equ 23 - 
74 Healthy endemic  (1.11) Neg Neg Neg - 45, 41 
75 Healthy endemic  (1.16) Neg Neg Neg - - 
76 Healthy endemic  (1.37) Neg Neg Neg - - 
77 Healthy endemic  (1.42) Neg Neg Neg - - 
78 Healthy endemic  (1.49) Neg Neg Neg - 66, 41 
79 Healthy endemic  (1.95) Neg Neg Neg 23 - 
80 Healthy endemic  (2.47) Neg Neg Pos 23 58, 41, 39, 18 
81 Healthy non-endemic (0.53) Neg Neg Neg - 41 
82 Healthy non-endemic (0.60) Neg Neg Neg 41, 23 41 
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Sample Sample Group 
DOC 
IgG
a
 
iPCR 
interpretation 
2-Tier 
Interpretation
b
 
EIA 
Interpretation 
IgM WB 
Bands 
IgG WB Bands 
83 Healthy non-endemic (0.78) Neg Neg Equ - - 
84 Healthy non-endemic (0.80) Neg Neg Pos - - 
85 Healthy non-endemic (0.86) Neg Neg Neg - - 
86 Healthy non-endemic (0.90) Neg Neg Neg - 58, 45 
87 Healthy non-endemic (1.09) Neg Neg Neg - 66, 58, 45, 41 
88 Healthy non-endemic (1.15) Neg Neg Neg - 41 
89 Healthy non-endemic (1.17) Neg Neg Neg - 41 
90 Healthy non-endemic (1.77) Neg Neg Neg 23 - 
91 Healthy non-endemic (2.06) Neg Neg Neg 23 - 
92 Healthy non-endemic (2.09) Neg Neg Neg - - 
 
a 
Values shown represent the ΔCq above (gray shading) or below (parenthesis) the positive call threshold Cq value determined using an antigen specific 
multiplier of the SD above the mean value for a set of healthy individuals for each antigen/isotype combination. 
b
2-tier results established by standard ELISA and IgG/IgM immunoblot
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Overall, iPCR provided increased sensitivity and specificity compared 
to 2-tier testing results (Figure 17). 
 
Figure 17. DOC fusion antigen IgG iPCR demonstrated improved sensitivity 
and specificity compared to 2-tier testing.  CDC Research Panel II was tested 
in a blinded fashion using DOC iPCR for IgG reactivity. Each dot represents a 
single individual replicate and the black horizontal lines represent the mean 
Cq value for all individuals within each category.  Filled circles represent 
samples that were 2-tier positive with open circles signifying 2-tier negative 
status.  A positive threshold value was established using a multiplier of the 
standard deviation (SD) above the mean value with the ΔCq threshold (gray 
horizontal line) representing a value of zero.  Sensitivity and specificity for 
iPCR, each tier and combined 2-tier are listed. 
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iPCR replicated all 2-tier positive results.  Moreover, iPCR provided 
detection of an additional three early Lyme disease samples deemed 2-tier 
negative, leading to an overall sensitivity for iPCR of 0.69 with a 95% 
confidence interval (95% CI) of 0.50-0.84 compared to 2-tier at 0.59 (95% CI: 
0.41-0.76). The difference in sensitivity was primarily for early stage detection 
with sensitivity for iPCR at 0.55 (95% CI: 0.32-0.77) and 2-tier at 0.40 (95% 
CI: 0.19-0.64) for this category of samples specifically.  iPCR and 2-tier 
showed equivalent sensitivity for late stage Lyme samples at 0.92 (95% CI: 
0.62-1.0).  iPCR detected only a single false positive for a healthy endemic 
sample providing a specificity of 0.98 (95% CI: 0.91-1.0) as compared to 2-tier 
testing that detected two false positives for look-alike diseases providing a 
specificity of 0.97 (95% CI:0.88-1.0).  For comparison, the sensitivity and 
specificity for the ELISA first tier portion of the 2-tier test were calculated to be 
0.75 (95% CI: 0.57-0.89) and 0.77 (95% CI: 0.64-0.87), respectively.  These 
data suggested that while the DOC IgG iPCR assay may be less sensitive 
than the ELISA, our assay has improved specificity over the first tier test. 
Discussion 
There is an urgent need for development of new tools for improved 
diagnosis of Lyme disease.  This study describes a sensitive, specific and 
quantitative Lyme disease diagnostic using iPCR detection of host IgG 
antibody binding to a single recombinant hybrid antigen that demonstrates 
improved results compared to the 2-tier testing protocol. 
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The iPCR Approach is a Repeatable Method that Shows Limited 
Background Variability Across a Healthy Population 
Repeatability is a key parameter of any newly developed diagnostic 
test that provides confidence the test will identify individuals as disease 
positive or negative in a reproducible manner across the inherent variability of 
a human population.  iPCR has been shown to be a reproducible approach for 
the detection of other targets [158, 159], although this method generates a 
background signal in the absence of the analyte being detected [160].  The 
background signal has been attributed to non-specific binding of the 
oligonucleotide labelled secondary antibody, similar to results observed for 
other immuno-diagnostics [125].  Although a number of approaches have 
been proposed to minimize the level of background amplification [121, 161, 
162], no approach to date has proven successful at completely eliminating the 
background signal.  For detection of Lyme disease, we propose that the 
background signal provides an intrinsic advantage over standard PCR based 
detection due to the buffer zone created between a negative sample and low 
level contamination that commonly creates problems for PCR based clinical 
diagnostic tests.  A positive iPCR result is required to generate an amplified 
signal above the background buffer zone.  In addition, critical to the success 
of this approach is a constant background that remains consistent between 
sample replicates and standardized across a healthy human population. 
In an effort to determine the consistency of the background 
amplification for the technique we tested the serum from a single healthy 
individual over eighteen replicates using iPCR and found the standard 
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deviation of the mean Cq values to be 0.39 and 0.73 for IgM and IgG, 
respectively with corresponding coefficients of variation of 1.34% and 2.30%.  
The accepted value for PCR sampling error is ~1 Cq [163] and the coefficient 
of variation for an ELISA based test is considered good at less than 15%  
[164].  These data indicate that our iPCR protocol can provide highly 
consistent and repeatable results across multiple replicates of a single 
sample.  We proceeded to test serum collected from 36 healthy individuals in 
duplicate for IgM and IgG reactivity using the same antigen to determine 
variability of the background across a healthy population.  Not unexpectedly, 
compared to the within sample repeatability analysis, we observed a slightly 
higher standard deviation of the mean Cq values of 0.79 and 0.84 for IgM and 
IgG, respectively and slightly increased corresponding coefficients of variation 
of 2.66% and 2.63%.  These data indicate that the assay maintains strong 
repeatability even when compounded with normal human population serum 
variability.  Taken together, these results indicate that the background 
variability for iPCR detection of host generated antibodies within and across a 
healthy human population is well within acceptable levels for the technique. 
Multiple Antigens are Required for Detection of Lyme 
Disease Across Multiple Stages/types of Disease 
Previous studies using recombinant antigens have indicated that no 
single antigen tested to date has the capability to diagnose Lyme disease 
across the multiple stages and/or types of disease manifestation [111].  A 
panel of eight antigens was generated for use in the iPCR assay. These 
proteins were selected based on previous studies that identified B. burgdorferi 
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immuno-reactive antigens [102, 165-170].  We first examined the level of 
variability of the background amplification of each antigen across serum 
samples collected from healthy individuals for both IgM and IgG isotypes.  
Each antigen resulted in a unique background amplification mean and 
standard deviation for each antigen/isotype combination.  This indicated that 
each antigen/isotype combination performed uniquely using the current iPCR 
protocol.  These data provided the necessary parameters including the mean 
background Cq value and the standard deviation of that mean for 
determination of an individual call threshold for each antigen/isotype 
combination.  The call thresholds were established as the mean background 
Cq value minus a multiple of the standard deviation.  The multiplier of 
standard deviation was unique for each antigen/isotype combination and 
established based on the maximum multiplier that resulted in no false positive 
calls for the CDC Research Panel I, which served as the training set for 
optimization of our assay.  The ΔCq was calculated as the established 
threshold call Cq minus the Cq value of the sample.  A sample with a ΔCq 
value ≥0 was deemed positive by iPCR.  Using the panel of eight antigens, 
this approach duplicated 2-tier testing results with a single early Lyme disease 
patient sample (culture positive) testing positive by iPCR that was negative by 
2-tier, suggesting an increased level of sensitivity.  Samples from individuals 
in later stages of the disease (neurologic and arthritis) tended to test positive 
for multiple antigens.  
In addition to detecting the presence of host antibodies and 
subsequent disease diagnosis, it is important to determine the clinical stage 
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(i.e., neurological, arthritic, cardiac) of a patient to better understand disease 
progression.  Results from human serum panel iPCR testing classified both 
late Lyme arthritis samples as strongly positive for IgG using RevA and 
Crasp2 proteins with all other categories of samples testing negative for the 
same two proteins.  This result suggests that these two proteins may 
specifically illicit an immune response in arthritic Lyme disease as opposed to 
other types of Lyme disease.  Other studies have shown RevA to be 
expressed early in human infection [170] and it has been evaluated as a 
potential vaccine target [171] but no studies have yet linked it to a particular 
disease type such as arthritis.  Crasp2 has been shown to illicit a long-term 
immune response in a mouse model [172] and explored for use in serological 
assays [173] but similar to RevA, has yet to be correlated with a disease type.  
RevA and CRASP-2 have been demonstrated to bind fibronectin and factor H, 
respectively.  Interestingly, a theory has been proposed in which persistence 
of B. burgdorferi infection could be due to the organism coating itself in host 
macromolecules (i.e., fibronectin) resulting in a decreased immunogenicity 
combined with protection from complement mediated lysis thus leading to 
secondary and tertiary stages of the disease including late stage arthritis 
[174].  This hypothesis would support the preliminary result observed for 
these two antigens by iPCR testing.  However, additional samples would be 
required to further support these observations. 
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DOC Single Hybrid Antigen iPCR Detection of Host Generated IgG 
Antibodies Provides a Simple Quantitative Lyme Diagnostic 
Limited studies have shown promising results using antigens 
composed of multiple antigenic portions of various seroreactive proteins to 
detect B. burgdorferi antibodies in human patient sera [169, 175, 176].  
Demonstration of iPCR equivalency to 2-tier testing using a panel of antigens 
led us to surmise that a more simplified version of the protocol using a single 
hybrid antigen was likely to be successful.  Three antigens known to be 
seroreactive at different stages of the disease (DbpA, OspC and VlsE) were 
synthetically joined by combining the sero-reactive peptide portions of OspC 
[177] and VlsE [178] with the full length DbpA protein into a single 
recombinant hybrid antigen we termed ‘DOC’.  The mean background was 
established for sixteen healthy individuals using DOC and showed little 
variation (standard deviation of 0.57 and 0.51 for anti-B. burgdorferi IgM and 
IgG antibodies) similar to the full length antigens tested.  The DOC antigen 
was then used to test a CDC Research Panel I for anti-B. burgdorferi IgM and 
IgG antibodies for establishing a positive call threshold.  DOC iPCR IgG 
results demonstrated equivalent results to 2-tier testing with all 2-tier positives 
showing positive by iPCR.  The quantitation of the ΔCq for Lyme disease 
patients showed a trend with increasing average values from early Lyme 
acute (-1.61) to early Lyme convalescent (0.67) to late stage Lyme (2.39) 
suggesting a correlation of the amount of detectable B. burgdorferi antibody 
with disease stage.  Surprisingly, DOC iPCR IgM was negative for all samples 
tested including Lyme disease patient samples.  These results indicate that 
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only testing of the IgG fraction using the DOC hybrid antigen is necessary for 
Lyme disease diagnosis by iPCR and there exists a potential for 
determination of the stage of disease based on the ΔCq value. 
iPCR testing of the anti-B. burgdorferi IgG antibody fraction using the 
DOC hybrid antigen was successful at duplicating the 2-tier testing results for 
a small panel of samples.  We then proceeded to test a larger blinded panel of 
92 samples composed of serum from Lyme disease patients (early, cardiac, 
arthritis and neurologic), look-alike diseases (fibromyalgia, mononucleosis, 
multiple sclerosis, rheumatoid arthritis, severe periodontitis and syphilis) and 
healthy (endemic and non-endemic) individuals (CDC Research Panel II).  
iPCR demonstrated increased sensitivity (0.69) and specificity (0.98) 
compared to 2-tier testing (0.59 and 0.97), respectively.  iPCR provided the 
highest level of specificity when compared to each individual tier and was only 
surpassed in sensitivity by tier-1 ELISA testing (0.75) which also resulted in 
the lowest level of specificity (0.77).  A single neurologic Lyme disease patient 
tested negative by both iPCR and 2-tier testing.  This result is most likely due 
to the fact that the serum sample was taken 7 days post EM, which was likely 
too early in infection to produce an adequate immune response. 
Application of DOC IgG iPCR as a Future Lyme Diagnostic 
For clinical testing, larger cohorts are needed to further standardize the 
assay and establish the exact cut-off needed to classify the borderline-positive 
samples as healthy or Lyme disease positive. Currently, the DOC hybrid 
antigen is composed of B. burgdorferi B31 sequences.  Amino acid 
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sequences can vary between strains and species of Lyme disease Borreliae 
by as much as 24% for VlsE C6 [157], 10% for OspC PEPC10C [156] and 
44% for DbpA [179].  This may be limiting if an individual is infected with other 
strains or species.  It is likely that the incorporation of additional 
protein/peptide sequences from other species, such as B. afzelii or B. garinii, 
or other strains might further increase the sensitivity of the assay, especially 
when samples from patients with Lyme disease from Europe and other 
diverse locations are analysed. 
In summary, DOC IgG iPCR shows extraordinary potential as a novel 
diagnostic tool for identifying host generated antibodies against B. burgdorferi.  
It will be of interest to determine whether this test is useful for monitoring 
antibody titre changes over time in samples from patients after antibiotic 
therapy for Lyme disease to determine the stage of disease as well as 
exploration of specialty testing using this approach to determine the type of 
disease manifestation. 
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CHAPTER FOUR: 
CONCLUSION 
Synthesis and Implications 
Lyme disease is the most common tick-borne bacterial disease in 
North America.  According to the Centers for Disease Control and Prevention, 
Lyme disease is the fastest growing tick-born disease in North America, with 
greater than 30,000 annual confirmed cases reported in United States and an 
estimated 300,000 infections every year [13]. Borrelia burgdorferi is the 
causative bacterial agent of Lyme disease in the United States and a 
spirochete that stains gram negative.   Using microscopy, it is typically 
characterized by its corkscrew morphology and periplasmic flagella.  B. 
burgdorferi cycles between small rodents and hard ticks including Ixodes 
scapularis in the Northeastern and Midwestern United States and Ixodes 
pacificus in Western states [180]. The organism does not cause disease 
symptoms in the tick or the mouse, both of which serve as reservoir hosts.  
Lyme disease outbreaks typically correlate with seasonal changes in tick 
activity with the height of transmission during late spring. Humans are not a 
natural host for B. burgdorferi but are infected when fed upon by an infected 
tick, resulting in disease manifestation following transmission of the organism. 
Lyme disease is an immunopathologic response to Borrelia burgdorferi and 
has three stages of infection.  The first stage is an early, localized infection 
characterized by erythema migrans (EM) or a ‘bull's eye’ rash that appears 3 
to 30 days after a tick bite. This rash symptom is seen in about 75% of the 
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infected population. Other signs of early stage infection include fatigue, chills, 
fever, and headache.  The next stage of infection is an early, disseminated 
infection, which results from dissemination of spirochetes to distant tissues 
like joints, heart, bladder, central nervous system and secondary skin sites. 
The final stage of infection occurs late and is characterized by arthritis, 
carditis and meningitis [180].  Antibiotic treatment for a duration of two weeks 
has shown to be successful following proper diagnosis. If gone untreated, 
Lyme disease is often difficult to treat in the advanced stages [181]. No 
accepted vaccine is currently available for Lyme disease so improved 
methods for diagnosis and treatment are necessary and continue to be 
important areas of research interest. 
Accurate diagnosis of Lyme disease poses one of the greatest 
challenges to the clinical management of the disease.  Misdiagnosis is 
common as the clinical manifestations of the disease are not unique and 
detection of a B. burgdorferi infection is difficult and prone to misinterpretation 
[111, 129].  There is great need for the development of improved methods for 
the definitive diagnosis of Lyme disease.  iPCR is a powerful and highly 
versatile approach for the detection of protein antigens and the host response 
antibodies that are produced against those antigens [126, 162].  This 
methodology combines the sensitivity of PCR with the specificity and 
versatility of ELISA-based protocols [118] and is an excellent technical tool for 
detection of low level proteins including antibodies. 
The dissertation presented addresses the hypothesis that the 
application of iPCR to detection of B. burgdorferi infection will result in an 
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improved diagnostic method for detection of Lyme disease.  The studies used 
to support this theory focused on the development and application of iPCR for 
detection of host-generated antibodies to B. burgdorferi and comparison of 
the approach to the currently accepted diagnostic methods for Lyme disease 
using an experimental mouse model of infection as well as human Lyme 
patient serum samples. 
iPCR Demonstrates the Capability for Both Direct and 
Indirect Detection of Multiple B. burgdorferi Targets  
The iPCR methodology is similar to that of a two-sided (sandwich) 
immunoassay in which the target protein is acquired between a capture 
antibody or antigen and a reporter antibody (Chapter 2, Figure 4).  In contrast 
to an ELISA, which uses an enzyme/substrate detection system, the detection 
system for iPCR is quantitative PCR amplification of a specific DNA molecule 
conjugated to the reporter antibody [118, 120, 126, 162].  PCR amplification of 
the DNA reporter results in exponential amplification of the output signal 
allowing detection of rare biomarkers in complex biological samples [118, 122, 
149, 182-184].  Similar to enzyme immunoassays, the specificity and 
versatility of iPCR is determined by the specificity of the capture and reporter 
antibodies for the target antigen [162].  The flexibility of the iPCR approach 
was demonstrated by capture and direct detection of intact B. burgdorferi 
(Chapter 2, Figure 9) and indirect detection of host generated antibodies in 
serum of B. burgdorferi infected mice (Chapter 2, Figure 6) using a similar 
magnetic bead capture methodology.   Similarly, it was shown that a variety of 
antigens including intact spirochetes (Chapter 2, Figure 6) as well as single 
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recombinant antigens (Chapter 2, Figure 7) could be used to capture host-
generated antibodies in the serum of B. burgdorferi infected mice.  The 
flexibility of the iPCR approach is advantageous and important for a disease 
such as Lyme disease where measurement of a single disease marker is 
unlikely to provide a comprehensive diagnostic assay.  Although multiple 
target detection is compatible with other diagnostic systems [185], it has been 
suggested that with careful selection of multiple capture/reporter antibody 
combinations along with unique DNA reporter molecules, iPCR assays may 
be capable of concurrent detection of several protein biomarkers in the same 
sample [186].  This possibility of multiplex analysis of a single sample is 
particularly intriguing for the development of a detection method for Lyme 
disease biomarkers as it would provide the ability to identify and quantitate the 
presence of several B. burgdorferi antibodies and/or antigens at the same 
time (Chapter 3, Figure 10B) and ultimately could lead to the ability to 
determine the specific Borrelia species that caused the infection and/or to 
determine the disease stage of the patient.  We have demonstrated that using 
iPCR both IgM and IgG host antibodies generated against a B. burgdorferi 
infection could be captured and detected simultaneously using magnetic 
beads coated with single B. burgdorferi antigen (Chapter 2, Figure 7 and 8).  It 
is intriguing to extend this same concept to detection of not only additional 
host antibody isotypes such as IgA [185] or IgE [187] but also provide the 
capability of concurrent direct detection of B. burgdorferi antigens within the 
same sample.  This same multiplex-based approach would be difficult if not 
impossible with other diagnostic methods that typically employ a single 
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reporter molecule such as an enzyme that is incapable of differentiating 
multiple targets in a single sample.  It is important to note that multiplex 
detection of multiple antigen types for purposes of increasing specificity, 
species identification and/or disease staging would require improvements on 
the current iPCR protocol described here.  The current protocol does not 
differentiate between antigen types conjugated to the magnetic beads but only 
the host antibody isotypes that bind a single antigen type.  Methods for 
determining antibody binding to multiple bead conjugated antigens would 
require a more sophisticated approach that would combine the capability to 
distinguish both bead type and antibody binding status simultaneously.  This 
could theoretically be accomplished by combining a digital PCR approach 
[188] with established methods for multiplex microsphere analysis [189] in a 
single platform.  Although technically challenging, this could provide a viable 
method for multiplexing both antigens as well as antibody isotypes for a more 
complete picture of host immune response. 
iPCR Utilizing Intact B. burgdorferi Shows Improved 
Sensitivity Using a Mouse Model 
In addition to the ability to detect multiple targets, sensitivity is a key 
parameter required for diagnosis of Lyme disease particularly in the early 
stages of disease when levels of host antibody can be quite low.  Because of 
its signal amplification power, iPCR demonstrates a 100-10,000 fold increase 
in the typical detection limit of the ELISA [120].  The specificity and sensitivity 
of iPCR makes it a highly effective method for diagnosis of infectious 
diseases.  Indeed, iPCR has been used for ultrasensitive detection of viral 
 97 
and bacterial pathogens and antibodies [121, 125, 147-149, 190-194].  In 
recent years vast improvements have been made to iPCR protocols, 
surmounting many of the difficulties, such as high background and lack of 
reproducibility, which have impeded the use of iPCR as a microbiological 
diagnostic tool in clinical laboratories [127].  It was demonstrated that iPCR 
using intact spirochetes to capture host-generated antibodies provided earlier 
detection (day 11) than either a commercial ELISA (day 14) or standard 
immunoblot (day 21) for a murine infection model (Chapter 2, Figure 6).  
These data have strong implications for iPCR detection of Lyme disease in 
humans.  Typically, detection of host antibody response is less successful in 
early stage of Lyme disease due to extremely low levels of circulating 
antibodies to the spirochete.  A diagnostic method such as iPCR that 
demonstrates more sensitive, and hence earlier, detection of B. burgdorferi 
antibodies provides the opportunity to begin treatment in a timelier manner 
which will ultimately minimize complications due to infection. 
iPCR Using Recombinant Antigens Further Improves Sensitivity 
and Demonstrates Strong Correlation with a Commercial 
ELISA For Human Serum Samples 
The initial iPCR assay design for capturing host antibodies against B. 
burgdorferi employed magnetic beads coated with intact spirochetes.  
Although this method proved successful, it resulted in only a small positive 
difference between uninfected and infected mouse serum.  These data 
suggested that only a minor percentage of the proteins exposed on the 
surface of the B. burgdorferi were antigenic and therefore capable of 
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capturing host antibodies generated in response to a B. burgdorferi infection.  
It therefore seemed reasonable to hypothesize that the use of specific 
recombinant in vivo-expressed B. burgdorferi antigens as the bait for the host 
response antibodies would likely provide improved sensitivity.   The basis for 
this hypothesis was that magnetic beads coated in specific in vivo-expressed 
antigens would provide optimal presentation of an increased concentration of 
a specific target for host antibody capture as opposed to a reduced 
concentration of multiple targets that would be presented on the surface of a 
whole spirochete.  This was found to be the case as demonstrated by 
detection of host response antibodies against B. burgdorferi at day 7 post 
inoculation in the mouse model of infection using magnetic beads coated in 
two distinct recombinant antigens (Chapter 2, Figure 7) as opposed to at day 
11 post inoculation using magnetic beads coated with intact spirochetes 
(Chapter 2, Figure 6).  Although specificity was not analysed in these 
experiments, it also seemed likely that the use of single B. burgdorferi-specific 
in vivo-expressed antigens would reduce the opportunity for cross-reactivity, 
which may occur with a higher frequency when the antibody capture systems 
uses antigens that are highly conserved across microorganisms, such as 
flagellar proteins [195].  The use of carefully selected B. burgdorferi-specific 
antigens provided the opportunity to reduce or potentially eliminate cross-
reactivity, screen for the antigens that demonstrated the highest sensitivity 
and potentially apply a select multi-antigen approach that may detect 
antibodies developed against antigens differentially expressed across the 
disease spectrum.  As stated earlier, host generated antibodies during a B. 
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burgdorferi infection can vary significantly by the type and stage of infection, 
strain and species of the infecting spirochete as well as the range of immune 
responses elicited by different individuals.  All in all, our preliminary data using 
a mouse infection model demonstrated the feasibility and strong performance 
of iPCR-based detection of B. burgdorferi antibodies in infected animals.    
The next step in development of the iPCR-based assay for detection of Lyme 
disease was to determine applicability of the approach for testing in human 
samples. 
To determine preliminary feasibility for Lyme disease testing of human 
samples with our assay, the next step in development was to determine assay 
performance for a small cohort of individual samples.  Although promising, the 
improved sensitivity the iPCR-based method demonstrated over current 
methods with a mouse model may not accurately predict the performance and 
varied background encountered when testing human patient samples.  For 
instance, a population of individuals from different parts of the country would 
likely be exposed to a number of different strains and present potentially 
different immune responses to the same strain.  In addition, different immune 
histories (i.e., exposure to other pathogens) could also potentially affect test 
specificity, as antigens from microorganisms other that B. burgdorferi have the 
possibility of generating antibodies that are cross reactive with B. burgdorferi 
antigens.  To explore these issues, preliminary testing utilized a panel of 
human serum samples from Lyme positive and negative individuals whose 
disease status was determined by the Centers for Disease Control using a 
commercial ELISA for combined IgM/IgG reactivity to the VlsE C6 antigen.  
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iPCR analysis of the human panel for IgM and IgG individual reactivity using 
the VlsE C6 peptide antigen demonstrated strong agreement with the 
commercial ELISA (Chapter 2, Figure 8) and as mentioned earlier was able to 
separately quantitate both IgM and IgG response as opposed to the combined 
IgM/IgG measurement of the commercial ELISA.  All samples positive by 
ELISA resulted in a positive iPCR call for either IgM or IgG.   More 
importantly, a small subset of samples that tested equivocal or negative by 
ELISA was found to be positive by iPCR.  This result further supported the 
earlier mouse model observation of increased assay sensitivity for iPCR 
compared to existing methods.  In addition, iPCR demonstrated no false 
positive results for non-Lyme disease and healthy individuals suggesting high 
overall specificity for the assay.  Due to the small sample size, these results 
were considered preliminary and required additional testing of human 
samples to support these conclusions.  Nonetheless, the overall results 
provided strong evidence for iPCR applicability to Lyme disease testing in 
human samples as a more sensitive method for indirect detection of host 
generated antibodies. 
iPCR Provides a Potential Method for Direct Detection of B. burgdorferi 
Indirect detection of host immune response by ELISA and immunoblot 
is the current accepted method for diagnosis of Lyme disease [106].  PCR 
detection is not recommended under CDC guidelines and culture of the 
organism from patient blood or tissue is not typically undertaken in a clinical 
setting [111].  This is primarily due to the fact that B. burgdorferi spirochetes 
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are found transiently in blood, in such low numbers (0.1-1.0 cfu/ml) and 
require more specialized culture conditions than other organisms [111].  Due 
to the fact that iPCR has demonstrated success at detection of low levels of 
organism in bodily fluids for other pathogens [121, 122], it was important to 
determine the potential for applying the same approach for direct detection of 
B. burgdorferi in blood.  Results with a mouse model (Chapter 2, Figure 9) 
demonstrated that direct capture and detection of B. burgdorferi whole 
organism from blood using iPCR did not reach adequate levels of sensitivity 
needed based on the predicted low levels of cultivable cells per millilitre of 
blood in an active human infection.  The iPCR method reproducibly detected 
1,000 spirochetes/ml; however, detection of spirochetes in human blood 
would require at least 1000-fold greater sensitivity.  There exists potential to 
use iPCR as opposed to PCR for earlier detection of enriched blood culture 
positive samples as it not only directly detects B. burgdorferi proteins but also 
provides minimal chance of false positive results due to laboratory 
contamination, which is a major challenge for PCR detection methods.  
Additional method development for this purpose would be required and would 
include testing of alternative antibodies for increased capture sensitivity and 
protocol optimization for spirochete capture in blood culture medium. 
The preliminary work described in the first section of this dissertation 
provides the initial report for the first successful application of iPCR for indirect 
detection of Lyme disease.  Methodologies and current limitations for 
detection of both host response antibodies to a B. burgdorferi infection and 
the spirochete itself were demonstrated suggesting potential applications as a 
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new and more sensitive Lyme disease diagnostic using primarily indirect 
detection of host generated antibodies.  With initial success in human 
samples, the next stage of development comprised expanded development of 
the assay and qualification for testing of human Lyme samples. 
iPCR Assay Multi-Antigen Development and 
Qualification as a Human Lyme Diagnostic 
With promising results for human sample testing with our iPCR assay, 
the next step in development was to determine the repeatability and 
background signal of the iPCR assay for human samples collected from 
healthy individuals.  iPCR, similar to other immuno-based detection methods 
such as ELISA, results in a normal background signal attributed to non-
specific binding of the detection reagents to the solid support matrix.  The 
presence of a background signal makes it important to determine the 
variability of the background signal for both the technique itself as well as 
normal variation within the healthy human population.  Intra-assay variation 
was tested by examining multiple replicates of the same serum sample for 
both IgM and IgG reactivity with a single antigen (Chapter 3, Figure 11), which 
resulted in strong repeatability for the assay itself.  This result was expected 
based on a small number of replicate samples tested during earlier 
development work.  Of more interest was the variation across a normal 
human population to determine if the background was indeed reproducible 
across groups of healthy individuals.  A normal background is important for 
immunoassays like iPCR due to the need to establish the range of values for 
healthy individuals to determine the threshold cut-off value for the assay that 
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distinguishes a negative from a positive result.  Intra-assay human population 
variability (Chapter 3, Figure 12) demonstrated a slight increase above the 
intra-assay technique variability.  This result is not unexpected as different 
individuals with varying immune histories would likely not provide the same 
background values.  Following establishment of iPCR technique repeatability 
for human samples, the next step was to focus on improving the host antibody 
capture capabilities of the assay. 
Because of the limitations of direct detection of B. burgdorferi in patient 
samples, the majority of current Lyme disease diagnostics rely on detection of 
host response antibodies to B. burgdorferi infection as recommended by the 
CDC [114].  The first-tier ELISA is the most common type of test performed to 
detect antibodies against B. burgdorferi [111] but this method does pose 
some challenges to the clinical diagnosis of Lyme disease.  The major 
drawback to the approach is a lack of required standardization which leads to 
variation within and between commercial kits which can increase the potential 
for misdiagnosis [111].  Antibody capture using whole-cell sonicates of B. 
burgdorferi as the capture antigen(s) tends to lack specificity due to the 
presence of conserved, highly cross-reactive antigens [111].  An additional 
challenge to the accurate detection of Lyme disease is that there are multiple 
Borrelia species that are able to cause the disease [180].  Genetic variability 
has been documented across isolates [65, 111, 196-198], which suggests that 
different species and different clinical isolates of the same species may have 
distinct antigen expression profiles resulting in discrete serological patterns 
that may not be detectable by single antigen ELISA methods [111].  As a 
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result, immunodiagnosis of Lyme disease is highly dependent on antigen 
selection.  For this reason, a panel of multiple antigens was examined using 
iPCR to identify those antigens that demonstrate high sensitivity and 
specificity in our assay. 
A group of antigens previously shown to be sero-reactive in mammals 
(mouse or human) were expressed as recombinant proteins in E. coli.  iPCR 
background signal was then established for each antigen using a sample of 
healthy individuals.  Each antigen/isotype combination provided a unique 
mean amplification cycle and standard deviation (Chapter 3, Figure 14) for the 
cohort of healthy samples.  For any quantitative assay that generates a 
background signal in healthy samples, determining the positive call threshold 
first requires establishment of the mean value and standard deviation for 
healthy individuals.  Typically, three times the standard deviation above the 
mean is applied for determining the call threshold in ELISA based assays 
[164]. Although the threshold value cut-off for iPCR was determined using 
three times the standard deviation of the background amplification of serum 
from healthy individuals in the initial stages of development of the assay 
(Chapter 2, Figures 6-8) it became apparent that due to the variation in means 
and standard deviation values between antigens and antibody isotypes, each 
antigen/isotype pair would require a unique empirically determined multiplier.  
It was determined that the multiplier would be established by testing a panel 
of known Lyme positive and negative samples, supplied by the CDC, for each 
antigen/isotype combination and adjustment of the standard deviation 
multiplier to a minimal value that would correctly identify the status of all 
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positive samples.  Hence, the eight recombinant proteins were tested against 
a training panel of 32 human samples including Lyme patient samples from 
different stages/types of disease, look-alike diseases and healthy endemic 
and non-endemic controls (CDC Research Panel I).  The disease status for 
each sample had been established previously by standard two-tier testing 
using a first tier ELISA and second tier immunoblots for IgM and IgG.  iPCR 
confirmed all two-tier positive samples with an additional early Lyme sample 
testing positive by iPCR but negative by two-tier analysis (Chapter 3, Table 3 
and Table 4).  Similar to the higher sensitivity observed for iPCR detection of 
B. burgdorferi antibodies in the previous human panel and mouse model, this 
result further supported higher sensitivity detection of host generated 
antibodies compared with two-tier testing.  All samples negative by two-tier 
were similarly confirmed negative by iPCR also demonstrating the strong 
specificity of the approach. 
The current national guidelines for serological diagnosis of Lyme 
disease recommend two-tier testing, in which a positive ELISA is followed by 
immunoblot analysis for specific IgM and IgG antibodies [114].  Although the 
two-tier protocol has improved diagnosis of Lyme disease [111], analysis of 
immunoblot results requires technical expertise and is prone to subjectivity 
leading to potential misinterpretation [154].  In addition to increased sensitivity 
and specificity, a goal for examining the iPCR approach as a method for 
diagnosing Lyme disease was to apply a technique with objective quantitative 
results with minimized technical complexity as a potential to replace two-tier 
testing.  Although successful at demonstrating increased sensitivity, an iPCR 
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protocol that requires the use of a panel of individual B. burgdorferi antigens 
would impart an undesirable complexity to the assay.  This is due to the fact 
that each antigen would require testing of a separate fraction of serum for 
each individual.  Although IgM and IgG could be tested simultaneously due to 
the multiplex capability of iPCR, the existing panel of eight antigens would 
require testing of eight aliquots for each individual resulting in a more complex 
testing and analysis scheme.  A more efficient solution would be to combine 
appropriate antigens into a single hybrid antigen to further minimize the 
complexity of the iPCR method for Lyme disease. 
Numerous ELISA and immunoblot Lyme disease diagnostic methods 
have been developed using specific B. burgdorferi recombinant antigens 
[111].  Strong assay sensitivities have been shown for other Lyme disease 
diagnostics when multiple purified antigens are used in combination [144, 
169, 199].  Moreover the data presented herein as well as the data from other 
groups demonstrate that there is no one single B. burgdorferi antigen that 
appears to be diagnostic for Lyme disease (Chapter 3, Table 3 and [111]).  As 
opposed to utilizing a combination of full length proteins, our strategy involved 
expressing a recombinant hybrid protein using a design scheme that coupled 
known immunodominant peptides to a highly expressed, small and 
established seroreactive protein.  The DbpA antigen was selected as the full 
length “anchor” antigen, which has been shown to maintain uniformly high 
antibody titers in non-human primates throughout the course of disease [107, 
200].  The immunodominant peptides for both the VlsE and OspC antigens 
have been mapped [201, 202], studied [203, 204] and utilized in other 
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diagnostic formats [205, 206].  The synthetic peptide C6, which represents the 
invariable region of the VlsE protein is a strong target for IgG antibodies early 
in Lyme disease progression [144, 178].  The OspC-derived peptide, 
PEPC10, also has demonstrated a strong immune response in Lyme disease 
patient sera during early stages of infection [144, 177, 203].  We generated a 
recombinant hybrid protein that coupled the amino acid sequences of 
PEPC10 and C6 to the C-terminus of the full length DbpA protein (Chapter 3, 
Figure 15A).  The mean background and standard deviation in a healthy 
human population was determined for the hybrid antigen we termed ‘DOC’ 
(Chapter 3, Figure 15B). 
The DOC antigen was then tested in a similar manner as the panel of 
eight antigens for both IgM and IgG iPCR reactivity against the panel of 32 
human sera from CDC Research Panel I.  The DOC IgG results using iPCR 
confirmed two-tier testing results for positive samples with no discrepancies 
(Chapter 3, Figure 16).  Additionally, all look-alike disease and healthy 
samples tested similarly tested negative by both iPCR and two-tier testing 
(Chapter 3, Figure 16).  Surprisingly, all samples tested negative by DOC IgM 
iPCR for Lyme disease patient, look-alike disease and healthy samples.  
Taken together, these results indicated that only testing of the IgG fraction of 
a sample was required using the DOC antigen and iPCR for 100% correlation 
with the two-tier results supplied by the CDC.  Although surprising, this result 
indicated a unique and strong benefit to our approach.  Depending upon the 
stage of infection and antigen expression pattern, B. burgdorferi may elicit IgM 
and/or IgG antibody production [207].  The guidelines for immunoblot 
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interpretation for two-tier testing state that IgM or IgG criteria [99, 110] may be 
used in the first month of infection.  However, immunoblot interpretation is 
then limited to IgG criteria only after 4 weeks following disease onset, as IgM 
has been shown to persist post-treatment despite resolution of the infection, 
making interpretation difficult [98, 207].  This means the time-sensitive use of 
IgM may not only limit assay sensitivity in the event that IgG antibodies have 
not fully developed at time points just beyond 4 weeks of infection [208] but 
also contribute to the complexity, cost and convoluted analysis of the two-tier 
method.  Our preliminary result with the DOC antigen IgG reactivity indicated 
that only a single tier single isotype test was required to confirm two-tier 
testing resulting in a significantly simplified protocol for Lyme disease testing 
that avoids the controversy associated with IgM interpretation. 
Beyond IgM interpretation, immunoblot analysis for Lyme disease is 
subjective and provides only qualitative results for host antibody levels.  iPCR, 
due to the incorporation of quantitative-PCR, provides a means for 
quantitatively determining the level of host generated antibodies in a serum 
sample similar to the first-tier ELISA.  Beyond confirmation of overall two-tier 
results, the values established for each positive sample by iPCR for the panel 
of 32 samples appeared to correlate with disease stage (Chapter 3, Figure 
16).  For instance, early stage Lyme samples ranged from 0.45 to 1.24 with 
an average ∆Cq of 0.67 (SD=.038).  Later stage Lyme samples (neurologic 
and arthritis) had a ∆Cq range of 1.45 to 2.86 with an average of 2.39 
(SD=.64).  This equates to slightly more than 3-fold higher antibody titres on 
average in later stage disease samples.  These early results suggest the 
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possibility of applying iPCR for quantitatively estimating the stage of disease 
progression.  This could provide valuable information to help address 
difficulties in treating Lyme disease at later stages of progression.  These 
results should be considered preliminary and would be further supported with 
additional testing of well-characterized human samples. 
Following successful testing of DOC IgG iPCR using a panel of known 
human serum samples, we next tested our optimized assay against a larger 
blinded panel of 92 human serum samples (CDC Research Panel II).  The 
panel was similarly composed of samples from confirmed Lyme disease 
patients, patients with look-alike diseases and healthy individuals from 
endemic and non-endemic areas.  Confirmation of positive Lyme patient 
status was established by the presence of single or multiple EM, culture re-
isolation of live B. burgdorferi organism and B. burgdorferi locus specific PCR 
from EM skin samples.  The results from these analyses demonstrated the 
optimized single antigen approach was capable of detecting all two-tier 
positive samples with an additional three early Lyme disease patient samples 
detected by iPCR that were not detected by the two-tier protocol providing a 
sensitivity of 0.69 compared to 0.59 for two-tier testing (Chapter 3, Figure 17).  
Only a single false positive was observed for iPCR compared to two false 
positive samples for two-tier testing providing a slightly higher specificity (0.98 
compared to 0.97).  These results confirmed the trend evident in both the 
mouse model as well as earlier testing with other human panels, that iPCR is 
a more sensitive approach than two-tier testing for diagnosis of Lyme disease 
in human serum samples.  Additionally, iPCR results for specificity were also 
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slightly improved compared to the existing two-tier protocol.  Taken together, 
these results provide strong support for further exploring the potential to 
replace current complex and labour intensive two-tier Lyme disease testing 
with the simple, cost effective, objective and quantitative method of single 
hybrid antigen IgG iPCR. 
Impact on Human Lyme Disease Diagnosis 
Certain sectors of society including individuals within the medical 
community have referred to Lyme disease as a chronic infection that is 
difficult to treat and in some cases can require prolonged antibiotic treatment 
for later stage disease.  Although the CDC has issued recommended metrics 
for diagnosing individuals infected with B. burgdorferi [106], diagnoses are at 
the physician’s discretion.  Improper analyses of diagnostic test results from 
immunoblot analysis alone or the interpretation of IgM immunoblot banding 
patterns beyond four weeks of infection have resulted in controversial 
determinations of disease status.  In response to incorrect test analysis, 
suspected Lyme disease patients may undergo expensive, long-term 
intravenous antibiotic treatments.  This is in direct contradiction to results from 
more recent clinical trials [209] that found no significant difference in the 
outcome for Lyme disease positive or negative patients for prolonged 
antibiotic treatment as compared with placebo.  It has also been established 
that extended courses of antibiotic therapy administered beyond the 
recommended time course can actually negatively impact a patient’s health 
status [210].  A more objective and less complex diagnostic test for Lyme 
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disease, such as out iPCR assay, may provide a more concise laboratory 
result reducing the opportunity for misdiagnosis based on incomplete or 
misunderstood clinical laboratory data. 
Earlier diagnosis of Lyme disease typically has a strong prognosis for 
recovery with the recommended two week regiment of oral antibiotics [211].  
However, if gone undetected, progression of Lyme disease can result in 
cellular damage and long term physical ailment [212].  This means the earlier 
and more accurately a B. burgdorferi infection can be detected and proper 
treatment initiated, the better the outcome and the less chance for 
unnecessary treatment due to either a false positive results using existing 
testing or more radical treatment based on incomplete diagnostic results.  
Current controversies surrounding diagnosis and treatment of Lyme disease 
highlights the importance for an improved more sensitive and more specific 
diagnostic [213].  iPCR was demonstrated to have superior sensitivity to two-
tier testing with particular improvements for detection of early disease.  The 
DOC IgG optimized iPCR also demonstrated increased specificity over two-
tier testing resulting in fewer false positive results for the serum samples in 
the CDC Research Panel II.  The results for iPCR are quantitative and 
unambiguous and eliminate the need for IgM analysis, which remains a 
controversial topic in Lyme disease diagnostic research.  The potential to 
reduce analysis to a simple single tier will also reduce the cost and complexity 
of Lyme disease diagnosis, simplify test result analysis and provide a more 
timely analysis of samples reducing the time to treatment for individuals that 
test positive.  Taken together, iPCR detection of Lyme disease has 
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demonstrated the capability to provide a more effective means of diagnosing 
Lyme disease. 
Future Directions 
 
Reagent Optimization 
One of the strengths of our iPCR approach is the use of a liquid phase 
capture of host-generated antibodies using antigen coupled magnetic beads.  
To accomplish the conjugation, a single commercial kit chemistry was used 
based on an epoxy surface chemistry (Dynabeads Antibody Coupling Kit, 
Invitrogen, Carlsbad, CA).  Additional commercial methods are available for 
linking ligands (antigens, antibodies, proteins, etc.) to solid supports such as 
magnetic beads using a number of different covalent linkages.  The chemical 
reactions that facilitate ligand attachment are well characterized and proceed 
by attachment of biomolecules through common chemical groups. 
The diagnostic performance of a coupled antigen can be affected by 
the type and number of linkages formed between the bead and the protein.  
For example, if the approach for linking the antigen to the bead adversely 
affects the structure of the antigen, it could limit its effectiveness as a capture 
molecule.  This is particularly true for capture of antibodies generated against 
the secondary structure of the antigen.  A loss of signal could also result if the 
coupled ligand leaches from the magnetic beads, which would also adversely 
affect the shelf life of prepared beads.  It is important to consider whether 
conjugation chemistry introduces a charged group to the beads that could 
cause nonspecific binding of either proteins and/or the reporter 
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oligonucleotide to the beads.  A final consideration is a linkage chemistry that 
could alter the structure of the beads such as promoting aggregation and/or 
adversely affecting their binding characteristics.  These are all important 
considerations for design of antigen coupling to the magnetic beads that with 
testing of each functional group reactivity could provide for a more sensitive 
assay. 
The types of functional groups found in antigenic proteins typically 
used for attachment to magnetic beads and available in a commercial format 
include primary amines, sulfhydryls and carboxylic acids [214]. The most 
common functional target for immobilizing protein molecules is the amine 
group (–NH2). This group exists at the N-terminus of each polypeptide chain 
and in the side chain of lysine residues. Due to its positive charge at 
physiological conditions (pH 7.0), primary amines are usually located on 
protein surfaces and allow for bead conjugation without denaturing the protein 
structure [215]. This is highly advantageous so as to minimize impacts on 
antigen secondary structure that could hinder antibody recognition. The 
limitation to the amine group coupling is that different antigens have different 
numbers of amine groups and hence it is difficult to maintain a uniform 
coupling efficiency across distinct antigens. 
In addition to amines, the thiol group can be used for direct coupling 
reactions using sulfhydryl (–SH) groups which exist in the side chain of 
cysteine [215]. Cysteines are joined together between their side chains via 
disulfide bonds (–S–S–) and provide secondary and tertiary structure to 
proteins. As opposed to amine groups that can be directly coupled to beads, 
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sulfhydryl groups must be reduced to make them available for immobilization. 
Sulfhydryl groups typically are present in fewer numbers than primary amines 
providing a potential method of selective and directional immobilization. A 
repeated number of sulfhydryl groups (cysteine residues) could be added to 
the terminus of an antigen providing a conjugation that will likely orient every 
protein molecule in the same way on the beads. The only drawback to this 
type of coupling reaction is the need to reduce naturally occurring disulfide 
bonds that may be present in the primary sequence of the antigen to make 
sulfhydryl groups available for covalent attachment. 
In addition to amines and sulfhydryl groups, proteins also have 
carboxyl groups (–COOH) that can also be utilized for conjugation to beads 
[215]. This is based on attachment at the C-terminus of each polypeptide 
chain and any amino acid residues of either aspartic acid or glutamic acid. 
Due to their charge and similarity to amine groups, carboxyl groups are 
usually found on the surface of proteins making them readily available for 
attachment. Carboxylic acids can be used to link antigens to commercially 
available beads through the use of an intermediary reaction. This method 
does typically require activation with a water-soluble cross-linker making this 
linkage a slightly more technically complex. The advantage to this method of 
antigen conjugation to beads is the resulting bead surface has a low non-
specific binding of nucleic acids, which could minimize non-specific 
interactions with the iPCR reporter oligonucleotide. Overall, examination of 
different antigen conjugation methods has the potential to improve the existing 
iPCR protocol through reduction of the background signal with minimized 
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effects on the true signal thus providing overall increased sensitivity through 
reduction of non-specific interactions. 
In addition to antigen coupling, the other aspect of iPCR reagent 
development that could be improved is assembly of the secondary 
antibody/oligonucleotide complex. The existing method utilizes a commercial 
process for conjugation of streptavidin to the secondary antibody using a 
proprietary one-step process that requires no downstream purification 
methodology (Lightning Link Streptavidin, Innova Biosciences, Cambridge, 
UK). The reporter oligonucleotide is synthesized with a terminal biotin group 
and a bridge between the two molecules is formed through the biotin-
streptavidin interaction. Although successful, this method has the potential to 
introduce background signal based on unconjugated free oligonucleotide 
and/or reporter antibody lacking the oligonucleotide. A more efficient method 
would be to avoid the use of bridging molecules and directly conjugate the 
oligonucleotide and reporter antibody. This could be accomplished through a 
proprietary commercial synthesis (Chimera Biotec, Germany) or a 
commercially available kit based on incorporation of an amine group on the 5’ 
or 3’ end of the oligonucleotide followed by directed antibody conjugation 
(Innova biosciences, United Kingdom). Additional methods of 
oligonucleotide/antibody conjugation would require analysis to determine the 
effect on both the true signal and the background signal. 
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Decreasing Noise and Increasing Signal 
Most diagnostic assays have an inherent signal to noise ratio. In 
immunological-based assays, the signal is generated from the binding of the 
reporter molecule to its specific target with the noise due mainly to the binding 
of the reporter to any non-specific targets such as the matrix or other proteins. 
The higher the signal to noise ratio, the more an assay can sensitively detect 
its target above the call threshold. All iPCR methods developed to date have 
noise due to inherent background amplification similar to the background 
observed with other immuno-specific methods (i.e., ELISA) [127]. Testing of 
our iPCR method (data not shown) was undertaken at the preliminary stages 
of assay development to both increase the signal and decrease the noise in 
our particular assay design (iPCR with magnetic beads, streptavidin/biotin 
bridged antibody/oligo). Different methods of bead blocking (Milk, blotto, BSA, 
commercial proprietary, etc.) were tested with no detectable change in 
background noise. Beads were also pre-incubated with naive serum from the 
same (mouse to mouse) as well as different species (rabbit to mouse) again 
with no detectable change in signal or background amplification. Additional 
experiments explored the potential for background contribution from unbound 
oligonucleotide and it was finally determined that, similar to other methods, 
the background signal in our iPCR assay predominated from non-specific 
binding of the secondary antibody to the magnetic beads. 
One possible alternative approach for reducing the iPCR background 
signal that remains to be explored is to replace the oligonucleotide-labeled 
secondary antibody with a different type of reporter molecule. Protein A, 
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Protein G, Protein A/G hybrids and Protein L all bind antibodies with different 
affinity based on species and isotype. These proteins have been explored as 
antibody reporter conjugates for Lyme disease ELISA based detection in zoo 
animals, game animals and hunting dogs [216, 217] and have shown good 
specificity for other infectious diseases [218, 219]. With the current optimized 
DOC IgG iPCR protocol, the most likely candidate would be Protein A/G but 
all antibody binding protein family members could be tested for application to 
iPCR detection of host generated antibodies in human serum samples. In 
contrast to decreasing the background noise of the assay, increasing the 
positive signal has the potential to also provide a more sensitive test. This 
could be accomplished by exploring other more sensitive and more complex 
reporter systems such as gold nanoparticles [220], electroconduction [221] or 
surface plasmon resonance [222]. However, the most applicable to the 
existing protocol would be to expand on the number of B. burgdorferi peptides 
in the hybrid antigen. This would require mapping the immunodominant 
peptides on known B. burgdorferi antigens. Besides the VlsE (C6) and OspC 
(PEPC10) antigens, this has only been accomplished on limited B. burgdorferi 
antigens to date [223-226]. Future studies aimed at epitope mapping of the 
protein panel that performed well with human samples (Chapter 3 Table 4) 
has potential to provide additional peptides to enhance the existing DOC 
hybrid antigen. It is also possible to predict conserved peptide antigens based 
on in-silico alignment of gene sequences from multiple species/strains. For 
example, an alignment of DbpA sequences for a number of strains and 
species (Figure 18) permits the prediction of a potential conserved B. 
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burgdorferi peptide that could be seroreactive. Additional antigens known or 
suspected to be seroreactive in humans (Chapter 1) would also provide an 
additional source of potential targets. 
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Figure 18. The DbpA antigen shows conservation at the Borrelia species level. An alignment of DbpA sequences from multiple 
strains for B. burgdorferi (top panel), B. garinii (middle panel) and B. afzelii (bottom panel) show regions of conservation for 
each species (gray highlight) that could function as peptide targets for further immuno-PCR development.  
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Additional Development and Testing 
In addition to work aimed at improving the sensitivity and specificity of 
the iPCR assay, it is important to consider practical aspects related to the 
future clinical application of iPCR for routine diagnosis of Lyme disease. 
Additional development goals include: (1) increasing throughput, (2) more 
precisely defining measures of background, sensitivity and specificity, and (3) 
broadening the diagnostic capability of the assay. 
The current protocol as published requires manual processing of 
individual samples. This not only provides for a more laborious and costly 
method but introduces the potential for human error. To increase throughput, 
a number of commercially available systems (plate washers, robotic liquid 
handlers, magnetic bead separators) have been developed for automated 
processing of magnetic bead based assays that can function using a 96-well 
plate format. A 96-well plate format would not only increase throughput but 
also provide more seamless compatibility with downstream qPCR analysis. 
Beyond commercially available units, there is the potential to automate the 
entire process in a microfluidic-type system that would combine both magnetic 
bead capture of host antibodies and PCR signal amplification in a single 
enclosed system. By increasing throughput, the efficiency of processing and 
more importantly repeatability would make transferring the protocol to a 
clinical setting more practical. 
A higher throughput and more automated protocol will provide the 
opportunity to increase the numbers of samples to attain a statistically 
stronger measurement of the healthy human background to contribute to a 
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more accurate call threshold. It is also important to analyse an increased 
number of samples similar to the types already tested in the CDC research 
panels (Lyme early, Lyme late, look-alikes, healthy endemic and non-
endemic) to provide a more robust estimate of the specificity and sensitivity of 
the iPCR assay. Increasing the number of Lyme patient and healthy samples 
tested will increase the overall confidence in assay performance and 
potentially move the assay closer towards clinical readiness. 
Although it is important to continue to refine the iPCR approach for 
application to Lyme disease it is important to emphasize that the existing 
protocol is currently designed for testing of human samples suspected of 
infection with B. burgdorferi. Additional Borrelia species, B. garinii and B. 
afzelii, are known to cause Lyme disease in Europe and the amino acid 
sequences of the antigenic proteins from these species may be divergent 
from those of B. burgdorferi . Therefore, infections resulting from B. garinii and 
B. afzelii may not be detected with the existing DOC antigen IgG iPCR assay. 
Testing of the same antigens (DbpA, C6 and PEPC10) from B. garinii and B. 
afzelii could provide a useful diagnostic for European Lyme patients but would 
require similar validation testing to determine the sensitivity and specificity of 
the refined antigen targets. In addition to humans, domestic animals such as 
dogs and horses are also known to suffer from Lyme disease as a result of 
infection with B. burgdorferi. It would be important to determine whether the 
DOC IgG protocol developed for humans would be applicable to Lyme 
disease testing in animals. Using the existing protocol, this would simply 
require either replacing the secondary reporter antibody with a species 
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specific antibody or testing of the newly proposed protein A/G reporter 
system. With additional design and development studies, iPCR application for 
diagnosis of Lyme disease has broad potential as a diagnostic platform. 
In total these future studies will provide insight into the applicability of 
iPCR for diagnosis of Lyme disease by optimizing the existing methods and 
expanding the protocol for more universal application with the goal of 
transferring the assay into a clinical setting for routine testing. This would help 
to improve diagnosis and ultimately treatment of a controversial and 
potentially debilitating infectious disease. 
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